ciprofloxacin has been researched along with Chronic Illness in 212 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| " To explore the potential therapeutic benefit of roxithromycin in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), this study compared the effect of roxithromycin with ciprofloxacin and aceclofenac." | 9.19 | Clinical efficacy of roxithromycin in men with chronic prostatitis/chronic pelvic pain syndrome in comparison with ciprofloxacin and aceclofenac: a prospective, randomized, multicenter pilot trial. ( Cho, YH; Choe, HS; Han, CH; Lee, SJ; Shim, BS, 2014) |
| "Sixteen consecutive ulcerative colitis patients with chronic refractory pouchitis (disease>4 weeks and failure to respond to>4 weeks of single-antibiotic therapy) were treated with a four-week course of ciprofloxacin 1 g/day and tinidazole 15 mg/kg/day." | 9.12 | Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis. ( Bennett, AE; Brzezinski, A; Fazio, VW; Lashner, BA; Lopez, R; Oikonomou, I; Remzi, FH; Shen, B; Sherman, KK, 2007) |
| "We compared baseline and post-therapy prostate specific antigen (PSA) in patients with chronic bacterial prostatitis who were treated with levofloxacin or ciprofloxacin." | 9.11 | Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. ( Kahn, JB; Schaeffer, AJ; Tennenberg, AM; Wu, SC, 2005) |
| "To investigate the value of Tc-99m ciprofloxacin imaging in the differential diagnosis of chronic bacterial prostatitis." | 9.10 | Tc-99m ciprofloxacin imaging in diagnosis of chronic bacterial prostatitis. ( Choe, W; Kim, S; Lee, SM; Moon, Y; Pai, SH; Ryu, JK; Seong, DW; Suh, JK, 2003) |
| "To compare the safety and efficacy of levofloxacin with that of ciprofloxacin for the treatment of chronic bacterial prostatitis." | 9.10 | Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. ( Bundrick, W; Heron, SP; Kahn, JB; Ray, P; Schiff, WM; Tennenberg, AM; Wiesinger, BA; Wright, PA; Wu, SC; Zadeikis, N, 2003) |
| "The efficacy and safety of three oral fluoroquinolones (lomefloxacin, levofloxacin, and ciprofloxacin) for the treatment of chronic osteomyelitis were analyzed." | 9.09 | Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis. ( Greenberg, RN; Newman, MT; Pectol, RW; Shariaty, S, 2000) |
| "To undertake a 1-year prospective economic evaluation of ciprofloxacin compared with usual antibacterial care (any antibacterial other than a quinolone) for the treatment of acute exacerbations of chronic bronchitis (AECB) in adults presenting with a type I or type II AECB." | 9.09 | Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. ( Grossman, R; La Forge, J; Lampron, N; Mukherjee, J; Torrance, G; Vaughan, D; Walker, V, 1999) |
| "The efficacy and safety of ciprofloxacin 500 mg bd for 28 days were assessed in 65 adult males with symptomatic bacterial prostatitis, from eight centres in Germany." | 9.09 | Ciprofloxacin in the treatment of chronic bacterial prostatitis: a prospective, non-comparative multicentre clinical trial with long-term follow-up. The German Prostatitis Study Group. ( Busch, W; Focht, J; Naber, KG, 2000) |
| "A multicentre double-blind randomized study was carried out to compare topical ciprofloxacin and topical gentamicin in the treatment of simple non-cholesteatomatous purulent chronic otitis media." | 9.08 | [Multicenter study comparing the efficacy and tolerance of topical ciprofloxacin (0.3%) versus topical gentamicin (0.3%) in the treatment of simple, non-cholesteatomaous chronic otitis media in the suppurative phase]. ( Abelló, P; Dicenta, M; Jiménez, R; Lorente, J; Maristany, M; Menem, J; Quesada, P; Sabater, F; Traserra, J; Viñas, J, 1995) |
| "9) suffering from bacterial exacerbation of chronic bronchitis have been randomly treated: 79 with co-amoxiclav (amoxicillin 875 mg+clavulanic acid 125 mg) twice daily, 69 with cefixime (400 mg) once daily, and 70 with ciprofloxacin (500 mg) twice daily for an average period of 10 days." | 9.08 | Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis. ( Beghi, GF; Casalini, A; Cazzola, M; Consigli, GF; Fiorentini, F; Giura, R; Madonini, V; Paizis, G; Tonna, M; Vinciguerra, A, 1995) |
| "To evaluate the efficacy of ciprofloxacin compared with tobramycin and placebo ear drops in the treatment of chronic suppurative otitis media without cholesteatoma." | 9.08 | Chronic otitis media treated topically with ciprofloxacin or tobramycin. ( Ben-David, J; Brodsky, A; Fradis, M; Larboni, J; Podoshin, L; Srugo, I, 1997) |
| "To evaluate the costs, consequences, effectiveness, and safety of ciprofloxacin vs standard antibiotic care in patients with an initial acute exacerbation of chronic bronchitis (AECB) as well as recurrent AECBs over a 1-year period." | 9.08 | A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group. ( Cook, R; Eastwood, C; Grossman, R; LaForge, J; Lampron, N; Mukherjee, J; Vaughan, D, 1998) |
| "A randomized, prospective, double-blind, double-dummy, multicenter study investigated the efficacy and safety of 10 days of oral therapy with grepafloxacin at 400 mg once daily, grepafloxacin at 600 mg once daily, or ciprofloxacin at 500 mg twice daily in 624 patients with acute bacterial exacerbations of chronic bronchitis." | 9.08 | Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily. ( Breisch, S; Chodosh, S; Lakshminarayan, S; Swarz, H, 1998) |
| "In a prospective, multicenter, double-blind study, the interval to clinical relapse in patients with acute bacterial exacerbations of chronic bronchitis from whom a pretherapy pathogen was isolated was compared following treatment with ciprofloxacin or cefuroxime axetil." | 9.08 | Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. ( Aneiro, L; Chodosh, S; Drehobl, M; Farkas, S; Kowalsky, S; McCarty, J; Shan, M; Tosiello, R, 1998) |
| "In this prospective, multicenter, double-blind study, the efficacy of ciprofloxacin was compared with that of clarithromycin as therapy for patients with acute bacterial exacerbations of chronic bronchitis (ABECB) from whom a pretherapy pathogen was isolated; the efficacy was measured by the infection-free interval." | 9.08 | Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. ( Anzueto, A; Barkman, HW; Chodosh, S; Kowalsky, S; Moesker, H; Schreurs, A; Shan, M; Siami, G; Stack, T, 1998) |
| "A total of 251 adults with chronic sinusitis were enrolled into this prospective multicentre, double-blind, double-placebo comparison of ciprofloxacin (500 mg twice daily) with amoxycillin/clavulanic acid (500 mg three times daily)." | 9.07 | A double-blind comparison of ciprofloxacin and amoxycillin/clavulanic acid in the treatment of chronic sinusitis. ( Beauvillain, C; Berche, P; Bordure, P; Legent, F, 1994) |
| "In 31 adult patients with cystic fibrosis (CF) who were chronically infected with Pseudomonas aeruginosa we examined the effect of giving regular three monthly oral ciprofloxacin." | 9.07 | Regular three monthly oral ciprofloxacin in adult cystic fibrosis patients infected with Pseudomonas aeruginosa. ( Assoufi, BK; Hodson, ME; Sheldon, CD, 1993) |
| "Clinical and bacteriological efficacy of topical ciprofloxacin hydrochloride was compared with that of intramuscular gentamicin sulfate in two groups composed of 30 patients each, all of whom were affected by chronic otitis media in the acute stage." | 9.07 | Topical ciprofloxacin vs intramuscular gentamicin for chronic otitis media. ( D'Errico, G; Esposito, S; Montanaro, C; Noviello, S, 1992) |
| "We undertook a prospective, randomized comparison of oral ciprofloxacin with standard parenteral therapies for the treatment of biopsy-proven osteomyelitis caused by susceptible organisms." | 9.06 | Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. ( Gentry, LO; Rodriguez, GG, 1990) |
| "The clinical and bacteriological efficacy of ciprofloxacin was studied in three groups composed of 20 patients each, all of whom were affected by chronic otitis media in the acute stage." | 9.06 | Topical and oral treatment of chronic otitis media with ciprofloxacin. A preliminary study. ( D'Errico, G; Esposito, S; Montanaro, C, 1990) |
| "This investigation compared the efficacy of oral formulations of amoxycillin/clavulanate and ciprofloxacin in acute exacerbations of chronic bronchitis." | 9.06 | Controlled prospective study of oral amoxycillin/clavulanate vs ciprofloxacin in acute exacerbations of chronic bronchitis. ( Ritzerfeld, W; Schmidt, EW; Ulmer, WT; Voss, E; Zimmermann, I, 1989) |
| "Oral ciprofloxacin was used at doses ranging from 500 mg to 1500 mg twice daily for 15 to 476 (mean 139) days for treatment of acute or chronic osteomyelitis in 38 patients, and acute arthritis in two." | 9.06 | Therapy of acute and chronic gram-negative osteomyelitis with ciprofloxacin. Report from a Swedish Study Group. ( , 1988) |
| "8 years) with chronic postsurgical osteomyelitis were treated with ciprofloxacin." | 9.06 | Treatment of chronic postsurgical osteomyelitis with ciprofloxacin. ( Hoogkamp-Korstanje, JA, 1987) |
| "Rifaximin-ciprofloxacin combination therapy is safe and objectively effective in chronic active refractory pouchitis and may salvage a significant percentage of 'at risk pouches'." | 7.73 | Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. ( Abdelrazeq, AS; Kelly, SM; Leveson, SH; Lund, JN, 2005) |
| "Methicillin-resistant Staphylococcus aureus (MRSA) is an increasing problem for patients with cystic fibrosis (CF)." | 7.73 | Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis. ( Conway, SP; Denton, M; Nadesalingam, K, 2005) |
| "We report a case of ciprofloxacin-induced acute non-oliguric renal failure that developed in a patient with chronic glomerulonephritis." | 7.73 | [Ciprofloxacin-induced acute non-oliguric renal failure in patient with chronic glomerulonephritis]. ( Czekalski, S; Niemir, ZI; Nowak, A; Paszkowska, M, 2005) |
| "The purpose of this study, conducted on patients with gingivitis and periodontitis, was twofold: to find out the serum and gingival crevicular fluid concentration of ciprofloxacin, which is a common drug used effectively against Actinobacillus actinomycetemcomitans and to determine the effects of ciprofloxacin administration on clinical parameters." | 7.73 | The gingival crevicular fluid ciprofloxacin level in subjects with gingivitis and periodontitis, and its effects on clinical parameters. ( Kara, C; Kavrut, F; Orbak, R; Sahin, T; Tezel, A; Yagiz, H; Yucel, O, 2005) |
| " The purpose of this study was to determine the serum and gingival crevicular fluid, or GCF, concentrations of systemic ciprofloxacin in patients with periodontitis." | 7.72 | Serum and gingival crevicular fluid levels of ciprofloxacin in patients with periodontitis. ( Bozkurt, A; Cağlayan, F; Dinçel, A; Tözüm, TF; Yildirim, A, 2004) |
| "Twice daily ciprofloxacin @ 500 mg for 28 days proved to be the most cost effective treatment for chronic bacterial prostatitis." | 7.71 | Cost effectiveness model comparing trimethoprim sulfamethoxazole and ciprofloxacin for the treatment of chronic bacterial prostatitis. ( Kaplan, S; Kurzer, E, 2002) |
| "With the aim to estimate the clinical and immunological efficiency of the ciprofloxacin (cifloxinal) 105 patients with acute (51), subacute (19) and chronic (35) brucellosis were studied." | 7.71 | [Ciprofloxacin in the treatment of patients with brucellosis]. ( Duĭsenova, AK; Kurmanova, GM; Kurmanova, KB, 2002) |
| "Seventeen adult patients with chronic osteomyelitis were treated with oral ciprofloxacin, 750 mg twice daily." | 7.68 | Oral ciprofloxacin for treatment of chronic osteomyelitis. ( Bortoletto, ML; Brasil Filho, R; Carvalho, MC; Levi, GC; Lobo, IM; Mendonça, JS; Silva, ML; Trevisanello, C; Yamaguti, A, 1993) |
| "In a retrospective study, the clinical and microbiological efficacy of amoxycillin-clavulanic acid and ciprofloxacin were evaluated in outpatients observed within the previous year who were affected by acute purulent exacerbations of chronic bronchitis." | 7.68 | Comparative clinical and microbiological study of amoxycillin-clavulanic acid and ciprofloxacin in acute purulent exacerbations of chronic bronchitis. ( Beghi, G; Caratozzolo, O; Legnani, D; Lombardo, VM; Negretto, GG, 1992) |
| "A total of 16 men suffering from refractory chronic bacterial prostatitis caused by Escherichia coli was treated with ciprofloxacin for 4 weeks." | 7.68 | Refractory chronic bacterial prostatitis: a re-evaluation of ciprofloxacin treatment after a median followup of 30 months. ( Brähler, E; Schiefer, HG; Weidner, W, 1991) |
| "A group of fourteen patients who had chronic osteomyelitis and were treated with oral ciprofloxacin was compared with a group of twelve patients of similar age who had chronic osteomyelitis and received standard parenteral antibiotic therapy consisting of nafcillin, clindamycin, and gentamicin, singly or in combination." | 7.68 | Oral ciprofloxacin compared with standard parenteral antibiotic therapy for chronic osteomyelitis in adults. ( Calhoun, J; Cantrell, JS; Mader, JT, 1990) |
| "The efficacies of the quinolones ciprofloxacin and pefloxacin alone and in combination with rifampin were compared with those of vancomycin alone and in combination with rifampin in a rat model of chronic osteomyelitis caused by methicillin-resistant Staphylococcus aureus." | 7.68 | Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis. ( Dworkin, R; Kunz, S; Modin, G; Rich, R; Sande, M; Zak, O, 1990) |
| "Twenty-seven patients with chronic osteomyelitis were treated with oral ciprofloxacin, 500 mg (13 patients) or 750 mg (13) twice daily and one patient was treated with 300 mg twice daily intravenously." | 7.67 | Treatment of chronic osteomyelitis with ciprofloxacin. ( Davidson, JS; de Graaf, W; de Zwart, DF; Detmar, SJ; Hoogkamp-Korstanje, JA; Rijnks, J; van Bottenburg, HA; van Bruggen, J; Ypma, JF, 1989) |
| "Eighty hospital patients with acute purulent exacerbations of chronic bronchitis associated with Haemophilus influenzae, Streptococcus pneumoniae, Branhamella catarrhalis or Pseudomonas aeruginosa were treated with ciprofloxacin." | 7.67 | Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis. ( Baur, C; Davies, BI; Maesen, FP, 1986) |
| "Ciprofloxacin, a new carboxyquinoline antimicrobial agent, was compared with tobramycin in the treatment of chronic osteomyelitis due to Pseudomonas aeruginosa in rabbits." | 7.67 | Ciprofloxacin as therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa. ( Norden, CW; Shinners, E, 1985) |
| "Thirty courses of ciprofloxacin were given to 28 patients with complicated urinary tract infections mainly caused by Pseudomonas aeruginosa." | 7.67 | Ciprofloxacin therapy in complicated urinary tract infections caused by Pseudomonas aeruginosa and other resistant bacteria. ( Emmanuel, FX; Leigh, DA; Petch, VJ, 1986) |
| "The clinical efficacy and tolerability of ciprofloxacin (Bay o 9867), a new quinolone compound with broad antibacterial spectrum, was evaluated in 28 patients hospitalized in the first Clinic of Infectious Diseases, University of Naples, Italy, for chronic liver disease and affected by respiratory (RTI) or urinary tract infections (UTI)." | 7.67 | Ciprofloxacin in the treatment of urinary and respiratory tract infections in patients with chronic liver disease. ( Barba, D; Esposito, S; Galante, D; Giusti, G, 1986) |
| "Treatment with enrofloxacin would not be recommended for a bacterial organism intermediate or resistant in susceptibility to enrofloxacin since appropriate levels of enrofloxacin would not be attained." | 6.74 | Plasma and ear tissue concentrations of enrofloxacin and its metabolite ciprofloxacin in dogs with chronic end-stage otitis externa after intravenous administration of enrofloxacin. ( Cole, LK; Hillier, A; Kwochka, KW; Lehman, AM; Papich, MG; Smeak, DD, 2009) |
| " Patients were randomly divided into three groups of 30; the first group was dosed with pefloxacin 800 mg i." | 6.68 | Comparative activities of pefloxacin and ciprofloxacin in the treatment of chronic respiratory tract infections. ( Arcidiacono, MM; Cogo, R; Fraschini, F; Monzani, GP; Scaglione, F; Scamazzo, F, 1995) |
| " Ten adverse events were observed in seven patients and in four (7%) of these treatment had to be withdrawn." | 6.67 | Study of the efficacy and safety of ciprofloxacin in the treatment of chronic sinusitis. ( Barrault, S; Dobler, S; Ebbo, D; Fombeur, JP; Koubbi, G; Laurier, JN; Lecomte, F; Sorrel, N, 1994) |
| "The antibiotic treatment rate of chronic bacterial prostatitis (CBP) is low, and long-term administration can result in adverse events and bacterial resistance." | 5.38 | Preventive effect of selenium on chronic bacterial prostatitis. ( Cho, YH; Ha, US; Kim, HW; Kim, SJ; Lee, SJ; Woo, JC; Yoon, BI, 2012) |
| "Levofloxacin was the most potent antibiotic against all cystic fibrosis isolates tested, with MIC(90)s ranging from 8 to 32 microg/ml." | 5.36 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. ( Burns, JL; Dudley, MN; Griffith, DC; King, P; Lomovskaya, O, 2010) |
| "Ciprofloxacin was tested in the acute and chronic experimental E." | 5.27 | [Ciprofloxacin and cefotaxim: pharmacokinetic and therapeutic effectiveness in E. coli pyelonephritis in rats]. ( Boness, J; Marre, R; Schulz, E; Tietgen, K, 1986) |
| "The osteomyelitis was secondary to trauma in 12 patients, joint replacement in six, previous acute hematogenous infection in two and osteotomy in one." | 5.27 | Treatment of chronic osteomyelitis with ciprofloxacin. ( Mulier, JC; Stuyck, J; Verbist, L, 1987) |
| " To explore the potential therapeutic benefit of roxithromycin in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), this study compared the effect of roxithromycin with ciprofloxacin and aceclofenac." | 5.19 | Clinical efficacy of roxithromycin in men with chronic prostatitis/chronic pelvic pain syndrome in comparison with ciprofloxacin and aceclofenac: a prospective, randomized, multicenter pilot trial. ( Cho, YH; Choe, HS; Han, CH; Lee, SJ; Shim, BS, 2014) |
| "Primary: to compare one-off administration of boric acid powder with courses of 1% acetic acid and ciprofloxacin eardrops in treating active chronic otitis media." | 5.16 | A randomised controlled trial of active chronic otitis media comparing courses of eardrops versus one-off topical treatments suitable for primary, secondary and tertiary healthcare settings. ( Loock, JW, 2012) |
| "Sixteen consecutive ulcerative colitis patients with chronic refractory pouchitis (disease>4 weeks and failure to respond to>4 weeks of single-antibiotic therapy) were treated with a four-week course of ciprofloxacin 1 g/day and tinidazole 15 mg/kg/day." | 5.12 | Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis. ( Bennett, AE; Brzezinski, A; Fazio, VW; Lashner, BA; Lopez, R; Oikonomou, I; Remzi, FH; Shen, B; Sherman, KK, 2007) |
| "We compared baseline and post-therapy prostate specific antigen (PSA) in patients with chronic bacterial prostatitis who were treated with levofloxacin or ciprofloxacin." | 5.11 | Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. ( Kahn, JB; Schaeffer, AJ; Tennenberg, AM; Wu, SC, 2005) |
| "To investigate the value of Tc-99m ciprofloxacin imaging in the differential diagnosis of chronic bacterial prostatitis." | 5.10 | Tc-99m ciprofloxacin imaging in diagnosis of chronic bacterial prostatitis. ( Choe, W; Kim, S; Lee, SM; Moon, Y; Pai, SH; Ryu, JK; Seong, DW; Suh, JK, 2003) |
| "To compare the safety and efficacy of levofloxacin with that of ciprofloxacin for the treatment of chronic bacterial prostatitis." | 5.10 | Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. ( Bundrick, W; Heron, SP; Kahn, JB; Ray, P; Schiff, WM; Tennenberg, AM; Wiesinger, BA; Wright, PA; Wu, SC; Zadeikis, N, 2003) |
| "The efficacy and safety of three oral fluoroquinolones (lomefloxacin, levofloxacin, and ciprofloxacin) for the treatment of chronic osteomyelitis were analyzed." | 5.09 | Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis. ( Greenberg, RN; Newman, MT; Pectol, RW; Shariaty, S, 2000) |
| "To examine the pharmacokinetics of ciprofloxacin and fleroxacin in plasma and sputum of patients with an acute exacerbation of chronic bronchitis or bronchiectasis following the first dose and again during the third day of treatment." | 5.09 | The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing. ( Begg, EJ; Buttimore, RC; Graham, GG; Neill, AM; Robson, RA; Saunders, DA; Town, GI, 2000) |
| "To undertake a 1-year prospective economic evaluation of ciprofloxacin compared with usual antibacterial care (any antibacterial other than a quinolone) for the treatment of acute exacerbations of chronic bronchitis (AECB) in adults presenting with a type I or type II AECB." | 5.09 | Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. ( Grossman, R; La Forge, J; Lampron, N; Mukherjee, J; Torrance, G; Vaughan, D; Walker, V, 1999) |
| "The efficacy and safety of ciprofloxacin 500 mg bd for 28 days were assessed in 65 adult males with symptomatic bacterial prostatitis, from eight centres in Germany." | 5.09 | Ciprofloxacin in the treatment of chronic bacterial prostatitis: a prospective, non-comparative multicentre clinical trial with long-term follow-up. The German Prostatitis Study Group. ( Busch, W; Focht, J; Naber, KG, 2000) |
| "To compare 1 week of trimethoprim-sulfamethoxazole treatment and 1 week of ciprofloxacin treatment in HIV-infected patients with chronic diarrhea caused by I." | 5.09 | Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial. ( Fitzgerald, DW; Johnson, WD; Pape, JW; Verdier, RI, 2000) |
| "A multicentre double-blind randomized study was carried out to compare topical ciprofloxacin and topical gentamicin in the treatment of simple non-cholesteatomatous purulent chronic otitis media." | 5.08 | [Multicenter study comparing the efficacy and tolerance of topical ciprofloxacin (0.3%) versus topical gentamicin (0.3%) in the treatment of simple, non-cholesteatomaous chronic otitis media in the suppurative phase]. ( Abelló, P; Dicenta, M; Jiménez, R; Lorente, J; Maristany, M; Menem, J; Quesada, P; Sabater, F; Traserra, J; Viñas, J, 1995) |
| "9) suffering from bacterial exacerbation of chronic bronchitis have been randomly treated: 79 with co-amoxiclav (amoxicillin 875 mg+clavulanic acid 125 mg) twice daily, 69 with cefixime (400 mg) once daily, and 70 with ciprofloxacin (500 mg) twice daily for an average period of 10 days." | 5.08 | Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis. ( Beghi, GF; Casalini, A; Cazzola, M; Consigli, GF; Fiorentini, F; Giura, R; Madonini, V; Paizis, G; Tonna, M; Vinciguerra, A, 1995) |
| "The efficacy of ciprofloxacin was studied in the treatment of 22 patients with hospital infection of the lower respiratory tract: 10 patients with nosocomial pneumonia, 8 with exacerbation of chronic obstructive bronchitis, 3 with exacerbation of mucoviscidosis and 1 with bronchiectasis." | 5.08 | [Effectiveness of ciprofloxacin in the treatment of hospital infections of the lower respiratory tract]. ( Avdeev, SN; Belevskiĭ, AS; Chuchalin, AG; Novikov, IuK, 1997) |
| "To evaluate the efficacy of ciprofloxacin compared with tobramycin and placebo ear drops in the treatment of chronic suppurative otitis media without cholesteatoma." | 5.08 | Chronic otitis media treated topically with ciprofloxacin or tobramycin. ( Ben-David, J; Brodsky, A; Fradis, M; Larboni, J; Podoshin, L; Srugo, I, 1997) |
| "To evaluate the costs, consequences, effectiveness, and safety of ciprofloxacin vs standard antibiotic care in patients with an initial acute exacerbation of chronic bronchitis (AECB) as well as recurrent AECBs over a 1-year period." | 5.08 | A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group. ( Cook, R; Eastwood, C; Grossman, R; LaForge, J; Lampron, N; Mukherjee, J; Vaughan, D, 1998) |
| "A randomized, prospective, double-blind, double-dummy, multicenter study investigated the efficacy and safety of 10 days of oral therapy with grepafloxacin at 400 mg once daily, grepafloxacin at 600 mg once daily, or ciprofloxacin at 500 mg twice daily in 624 patients with acute bacterial exacerbations of chronic bronchitis." | 5.08 | Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily. ( Breisch, S; Chodosh, S; Lakshminarayan, S; Swarz, H, 1998) |
| "In a prospective, multicenter, double-blind study, the interval to clinical relapse in patients with acute bacterial exacerbations of chronic bronchitis from whom a pretherapy pathogen was isolated was compared following treatment with ciprofloxacin or cefuroxime axetil." | 5.08 | Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. ( Aneiro, L; Chodosh, S; Drehobl, M; Farkas, S; Kowalsky, S; McCarty, J; Shan, M; Tosiello, R, 1998) |
| "In this prospective, multicenter, double-blind study, the efficacy of ciprofloxacin was compared with that of clarithromycin as therapy for patients with acute bacterial exacerbations of chronic bronchitis (ABECB) from whom a pretherapy pathogen was isolated; the efficacy was measured by the infection-free interval." | 5.08 | Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. ( Anzueto, A; Barkman, HW; Chodosh, S; Kowalsky, S; Moesker, H; Schreurs, A; Shan, M; Siami, G; Stack, T, 1998) |
| "A total of 251 adults with chronic sinusitis were enrolled into this prospective multicentre, double-blind, double-placebo comparison of ciprofloxacin (500 mg twice daily) with amoxycillin/clavulanic acid (500 mg three times daily)." | 5.07 | A double-blind comparison of ciprofloxacin and amoxycillin/clavulanic acid in the treatment of chronic sinusitis. ( Beauvillain, C; Berche, P; Bordure, P; Legent, F, 1994) |
| "In 31 adult patients with cystic fibrosis (CF) who were chronically infected with Pseudomonas aeruginosa we examined the effect of giving regular three monthly oral ciprofloxacin." | 5.07 | Regular three monthly oral ciprofloxacin in adult cystic fibrosis patients infected with Pseudomonas aeruginosa. ( Assoufi, BK; Hodson, ME; Sheldon, CD, 1993) |
| "Clinical and bacteriological efficacy of topical ciprofloxacin hydrochloride was compared with that of intramuscular gentamicin sulfate in two groups composed of 30 patients each, all of whom were affected by chronic otitis media in the acute stage." | 5.07 | Topical ciprofloxacin vs intramuscular gentamicin for chronic otitis media. ( D'Errico, G; Esposito, S; Montanaro, C; Noviello, S, 1992) |
| "To assess whether chronic pulmonary colonisation with Pseudomonas aeruginosa in cystic fibrosis is preventable, 26 patients who had never received anti-pseudomonas chemotherapy were randomly allocated to groups receiving either no anti-pseudomonas chemotherapy or oral ciprofloxacin and aerosol inhalations of colistin twice daily for 3 weeks, whenever Ps aeruginosa was isolated from routine sputum cultures." | 5.07 | Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. ( Høiby, N; Koch, C; Valerius, NH, 1991) |
| "We undertook a prospective, randomized comparison of oral ciprofloxacin with standard parenteral therapies for the treatment of biopsy-proven osteomyelitis caused by susceptible organisms." | 5.06 | Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. ( Gentry, LO; Rodriguez, GG, 1990) |
| "The clinical and bacteriological efficacy of ciprofloxacin was studied in three groups composed of 20 patients each, all of whom were affected by chronic otitis media in the acute stage." | 5.06 | Topical and oral treatment of chronic otitis media with ciprofloxacin. A preliminary study. ( D'Errico, G; Esposito, S; Montanaro, C, 1990) |
| "This investigation compared the efficacy of oral formulations of amoxycillin/clavulanate and ciprofloxacin in acute exacerbations of chronic bronchitis." | 5.06 | Controlled prospective study of oral amoxycillin/clavulanate vs ciprofloxacin in acute exacerbations of chronic bronchitis. ( Ritzerfeld, W; Schmidt, EW; Ulmer, WT; Voss, E; Zimmermann, I, 1989) |
| "Oral ciprofloxacin was used at doses ranging from 500 mg to 1500 mg twice daily for 15 to 476 (mean 139) days for treatment of acute or chronic osteomyelitis in 38 patients, and acute arthritis in two." | 5.06 | Therapy of acute and chronic gram-negative osteomyelitis with ciprofloxacin. Report from a Swedish Study Group. ( , 1988) |
| "8 years) with chronic postsurgical osteomyelitis were treated with ciprofloxacin." | 5.06 | Treatment of chronic postsurgical osteomyelitis with ciprofloxacin. ( Hoogkamp-Korstanje, JA, 1987) |
| "A 58-year-old male developed fulminating musculoskeletal pain associated with third-time exposure to ciprofloxacin administered for treatment of chronic otitis media." | 4.85 | Ciprofloxacin-related acute severe myalgia necessitating emergency care treatment: a case report and review of the literature. ( Eisele, S; Garbe, E; Schneider, T; Somasundaram, R; Zeitz, M, 2009) |
| " This work is based on the development and characterization of lipid nanoparticles of solid phase incorporating two antibiotics, minocycline, and ciprofloxacin with antinociceptive properties and challenged them with a rat monoarthritis model using Sprague-Dawley adult male rats." | 3.88 | Antinociceptive antibiotics-loaded into solid lipid nanoparticles of prolonged release: Measuring pharmacological efficiency and time span on chronic monoarthritis rats. ( Bustos, G; Laurido, C; Martinez, JL; Valdes, C, 2018) |
| "The study included 50 patients with chronic prostatitis who showed hot uptake in seminal vesicles on Tc-99m ciprofloxacin imaging and eight patients who did not show hot uptake." | 3.81 | Chronic bacterial seminal vesiculitis as a potential disease entity in men with chronic prostatitis. ( Choe, WS; Choo, GY; Chung, YG; Hyun, IY; Kim, CH; Park, SH; Ryu, DS; Ryu, JK; Seong, DH; Suh, JK, 2015) |
| "Enoxacin was effective in 35%; ciprofloxacin (five publications) was used in 82 patients with 67% effectivity in otitis externa and otitis media and 61% effectivity in radical mastoid cavity infection." | 3.76 | The use of fluoroquinolones in chronic otitis suppurativa. ( Claes, J; Pattyn, SR; Valcke, HD; van Caekenberghe, DL; van de Heyning, PH, 1987) |
| "Rifaximin-ciprofloxacin combination therapy is safe and objectively effective in chronic active refractory pouchitis and may salvage a significant percentage of 'at risk pouches'." | 3.73 | Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. ( Abdelrazeq, AS; Kelly, SM; Leveson, SH; Lund, JN, 2005) |
| "Methicillin-resistant Staphylococcus aureus (MRSA) is an increasing problem for patients with cystic fibrosis (CF)." | 3.73 | Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis. ( Conway, SP; Denton, M; Nadesalingam, K, 2005) |
| "We report a case of ciprofloxacin-induced acute non-oliguric renal failure that developed in a patient with chronic glomerulonephritis." | 3.73 | [Ciprofloxacin-induced acute non-oliguric renal failure in patient with chronic glomerulonephritis]. ( Czekalski, S; Niemir, ZI; Nowak, A; Paszkowska, M, 2005) |
| "The purpose of this study, conducted on patients with gingivitis and periodontitis, was twofold: to find out the serum and gingival crevicular fluid concentration of ciprofloxacin, which is a common drug used effectively against Actinobacillus actinomycetemcomitans and to determine the effects of ciprofloxacin administration on clinical parameters." | 3.73 | The gingival crevicular fluid ciprofloxacin level in subjects with gingivitis and periodontitis, and its effects on clinical parameters. ( Kara, C; Kavrut, F; Orbak, R; Sahin, T; Tezel, A; Yagiz, H; Yucel, O, 2005) |
| " The purpose of this study was to determine the serum and gingival crevicular fluid, or GCF, concentrations of systemic ciprofloxacin in patients with periodontitis." | 3.72 | Serum and gingival crevicular fluid levels of ciprofloxacin in patients with periodontitis. ( Bozkurt, A; Cağlayan, F; Dinçel, A; Tözüm, TF; Yildirim, A, 2004) |
| "In a previous study in experimental Klebsiella pneumoniae pneumonia, the therapeutic potential of ciprofloxacin was significantly improved by encapsulation in polyethylene glycol-coated ("pegylated") long-circulating (STEALTH) liposomes." | 3.71 | Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection. ( Bakker-Woudenberg, IA; Guo, L; Mouton, JW; ten Kate, MT; Working, P, 2002) |
| "Twice daily ciprofloxacin @ 500 mg for 28 days proved to be the most cost effective treatment for chronic bacterial prostatitis." | 3.71 | Cost effectiveness model comparing trimethoprim sulfamethoxazole and ciprofloxacin for the treatment of chronic bacterial prostatitis. ( Kaplan, S; Kurzer, E, 2002) |
| "With the aim to estimate the clinical and immunological efficiency of the ciprofloxacin (cifloxinal) 105 patients with acute (51), subacute (19) and chronic (35) brucellosis were studied." | 3.71 | [Ciprofloxacin in the treatment of patients with brucellosis]. ( Duĭsenova, AK; Kurmanova, GM; Kurmanova, KB, 2002) |
| "A combination of rifaximin and ciprofloxacin was effective in patients with active chronic, treatment-resistant pouchitis, suggesting the need, in these patients, for treatment using antibiotic agents with wide antibacterial spectrum of activity." | 3.70 | Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. ( Brigidi, P; Campieri, M; Ferrieri, A; Gionchetti, P; Johansson, R; Poggioli, G; Rizzello, F; Rossi, M; Ugolini, F; Venturi, A, 1999) |
| "We prepared a composite of fibrin clot and ciprofloxacin for use as a biodegradable antibiotic delivery system with sustained effect for the treatment of chronic osteomyelitis." | 3.69 | Pharmacokinetic study of fibrin clot-ciprofloxacin complex: an in vitro and in vivo experimental investigation. ( Dounis, E; Giamarellou, H; Hatzigrigoris, P; Kanellakopoulou, K; Tsibinos, A; Tsourvakas, S, 1995) |
| "Sixty outpatients at the age of 65 to 75 years with exacerbated chronic bronchitis were treated with antibiotics: amoxycillin/clavulanic acid (20 patients), cefaclor (20 patients) and ciprofloxacin (20 patients)." | 3.69 | [Treatment of lower respiratory tract infections in the elderly]. ( Belousov, IuB; Efremenkova, OV; Komarova, VP; Sokolov, AV; Tishchenkova, IF, 1997) |
| "Seventeen adult patients with chronic osteomyelitis were treated with oral ciprofloxacin, 750 mg twice daily." | 3.68 | Oral ciprofloxacin for treatment of chronic osteomyelitis. ( Bortoletto, ML; Brasil Filho, R; Carvalho, MC; Levi, GC; Lobo, IM; Mendonça, JS; Silva, ML; Trevisanello, C; Yamaguti, A, 1993) |
| "In a retrospective study, the clinical and microbiological efficacy of amoxycillin-clavulanic acid and ciprofloxacin were evaluated in outpatients observed within the previous year who were affected by acute purulent exacerbations of chronic bronchitis." | 3.68 | Comparative clinical and microbiological study of amoxycillin-clavulanic acid and ciprofloxacin in acute purulent exacerbations of chronic bronchitis. ( Beghi, G; Caratozzolo, O; Legnani, D; Lombardo, VM; Negretto, GG, 1992) |
| "A total of 16 men suffering from refractory chronic bacterial prostatitis caused by Escherichia coli was treated with ciprofloxacin for 4 weeks." | 3.68 | Refractory chronic bacterial prostatitis: a re-evaluation of ciprofloxacin treatment after a median followup of 30 months. ( Brähler, E; Schiefer, HG; Weidner, W, 1991) |
| "A group of fourteen patients who had chronic osteomyelitis and were treated with oral ciprofloxacin was compared with a group of twelve patients of similar age who had chronic osteomyelitis and received standard parenteral antibiotic therapy consisting of nafcillin, clindamycin, and gentamicin, singly or in combination." | 3.68 | Oral ciprofloxacin compared with standard parenteral antibiotic therapy for chronic osteomyelitis in adults. ( Calhoun, J; Cantrell, JS; Mader, JT, 1990) |
| "The efficacies of the quinolones ciprofloxacin and pefloxacin alone and in combination with rifampin were compared with those of vancomycin alone and in combination with rifampin in a rat model of chronic osteomyelitis caused by methicillin-resistant Staphylococcus aureus." | 3.68 | Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis. ( Dworkin, R; Kunz, S; Modin, G; Rich, R; Sande, M; Zak, O, 1990) |
| "Twenty-seven patients with chronic osteomyelitis were treated with oral ciprofloxacin, 500 mg (13 patients) or 750 mg (13) twice daily and one patient was treated with 300 mg twice daily intravenously." | 3.67 | Treatment of chronic osteomyelitis with ciprofloxacin. ( Davidson, JS; de Graaf, W; de Zwart, DF; Detmar, SJ; Hoogkamp-Korstanje, JA; Rijnks, J; van Bottenburg, HA; van Bruggen, J; Ypma, JF, 1989) |
| "Eighty hospital patients with acute purulent exacerbations of chronic bronchitis associated with Haemophilus influenzae, Streptococcus pneumoniae, Branhamella catarrhalis or Pseudomonas aeruginosa were treated with ciprofloxacin." | 3.67 | Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis. ( Baur, C; Davies, BI; Maesen, FP, 1986) |
| "The efficacy and safety of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections was evaluated in 72 patients suffering from upper urinary tract infection (19 patients), deep soft tissue infection (16), chronic osteomyelitis (12), abscess (7), chronic otitis media (6), otitis externa (3) and bronchopneumonia (9)." | 3.67 | Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections. ( Daikos, GK; Daphnis, E; Dendrinos, C; Galanakis, N; Giamarellou, H; Stefanou, J, 1986) |
| "Ciprofloxacin, a new carboxyquinoline antimicrobial agent, was compared with tobramycin in the treatment of chronic osteomyelitis due to Pseudomonas aeruginosa in rabbits." | 3.67 | Ciprofloxacin as therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa. ( Norden, CW; Shinners, E, 1985) |
| "Thirty courses of ciprofloxacin were given to 28 patients with complicated urinary tract infections mainly caused by Pseudomonas aeruginosa." | 3.67 | Ciprofloxacin therapy in complicated urinary tract infections caused by Pseudomonas aeruginosa and other resistant bacteria. ( Emmanuel, FX; Leigh, DA; Petch, VJ, 1986) |
| "The clinical efficacy and tolerability of ciprofloxacin (Bay o 9867), a new quinolone compound with broad antibacterial spectrum, was evaluated in 28 patients hospitalized in the first Clinic of Infectious Diseases, University of Naples, Italy, for chronic liver disease and affected by respiratory (RTI) or urinary tract infections (UTI)." | 3.67 | Ciprofloxacin in the treatment of urinary and respiratory tract infections in patients with chronic liver disease. ( Barba, D; Esposito, S; Galante, D; Giusti, G, 1986) |
| "Approximately half the patients with ulcerative colitis who undergo restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) will subsequently have pouchitis, and among those patients, one fifth will have chronic pouchitis." | 3.30 | Vedolizumab for the Treatment of Chronic Pouchitis. ( Bressler, B; Danese, S; Escher, A; Feagan, BG; Ferrante, M; Gionchetti, P; Hart, A; Jairath, V; Jones, S; Lindner, D; Löwenberg, M; Shen, B; Silverberg, MS; Travis, S, 2023) |
| "Topical ciprofloxacin is a safe and uncomplicated ototoxic drug that is an effective antibiotic used in the treatment of refractory chronic otitis those dregs such as pseudomonas aerogenusa and staphylococci resistant to methicillin are responsible for it, which in the usual doses has not harmful effects on hearing hairy cells." | 2.79 | Comparison of local and systemic ciprofloxacin ototoxicity in the treatment of chronic media otitis. ( Samarei, R, 2014) |
| "Treatment with enrofloxacin would not be recommended for a bacterial organism intermediate or resistant in susceptibility to enrofloxacin since appropriate levels of enrofloxacin would not be attained." | 2.74 | Plasma and ear tissue concentrations of enrofloxacin and its metabolite ciprofloxacin in dogs with chronic end-stage otitis externa after intravenous administration of enrofloxacin. ( Cole, LK; Hillier, A; Kwochka, KW; Lehman, AM; Papich, MG; Smeak, DD, 2009) |
| "The value of antibiotics in the treatment of reactive arthritis (ReA) is still controversial." | 2.71 | Effect of a three month course of ciprofloxacin on the late prognosis of reactive arthritis. ( Hakola, M; Korpela, M; Luukkainen, R; Möttönen, T; Sanila, M; Toivanen, A; Uksila, J; Yli-Kerttula, T; Yli-Kerttula, U, 2003) |
| "Treatment with ciprofloxacin eardrops seemed to be at least as efficient as treatment with tobramycin." | 2.69 | [Local treatment of purulent chronic otitis media with ciprofloxacin]. ( Ben-David, J; Brodzki, A; Fradis, M; Larboni, J; Podoshin, L; Srugo, I, 1998) |
| "Ciprofloxacin was not detected in the plasma of any child." | 2.68 | Topical ciprofloxacin for otorrhea after tympanostomy tube placement. ( Force, RW; Hart, MC; Nahata, MC; Plummer, SA; Powell, DA, 1995) |
| " Patients were randomly divided into three groups of 30; the first group was dosed with pefloxacin 800 mg i." | 2.68 | Comparative activities of pefloxacin and ciprofloxacin in the treatment of chronic respiratory tract infections. ( Arcidiacono, MM; Cogo, R; Fraschini, F; Monzani, GP; Scaglione, F; Scamazzo, F, 1995) |
| " In 4 patients, treatment was discontinued prematurely after an adverse event." | 2.68 | Multicenter study of the efficacy and safety of oral ciprofloxacin in the treatment of chronic suppurative otitis media in adults. The French Study Group. ( Gehanno, P, 1997) |
| "Ciprofloxacin appears to be an effective treatment of chronic otitis media, and superior to amoxycillin/clavulanic acid." | 2.67 | Controlled prospective study of oral ciprofloxacin versus amoxycillin/clavulanic acid in chronic suppurative otitis media in adults. ( Beauvillain, C; Berche, P; Bordure, P; Legent, F, 1994) |
| " Ten adverse events were observed in seven patients and in four (7%) of these treatment had to be withdrawn." | 2.67 | Study of the efficacy and safety of ciprofloxacin in the treatment of chronic sinusitis. ( Barrault, S; Dobler, S; Ebbo, D; Fombeur, JP; Koubbi, G; Laurier, JN; Lecomte, F; Sorrel, N, 1994) |
| " Eight adverse effects were observed in five patients and treatment had to be discontinued in one case." | 2.67 | Study of the efficacy and safety of ciprofloxacin in the treatment of chronic otitis. ( Barrault, S; Dobler, S; Ebbo, D; Fombeur, JP; Koubbi, G; Laurier, JN; Lecomte, F; Sorrel, N, 1994) |
| "Ciprofloxacin has been shown to be effective against a wide range of gram-negative and gram-positive organisms." | 2.66 | Ciprofloxacin for the treatment of chronic ear disease. ( Parnes, SM; Piccirillo, JF, 1989) |
| "Ofloxacin kinetics were influenced by renal dysfunction encountered in patients with ascites." | 2.38 | Pharmacokinetics of fluoroquinolones in hepatic failure. ( Gaillot, J; Montay, G, 1990) |
| "Ciprofloxacin was effective against Staphylococcus aureus, but Pseudomonas aeruginosa strains were ciprofloxacin resistant." | 1.72 | Analysis of pathogens and antimicrobial treatment in different groups of patients with chronic otitis media. ( Budzyńska, A; Gospodarek-Komkowska, E; Janiak-Kiszka, J; Kaźmierczak, H; Kaźmierczak, W; Nowaczewska, M, 2022) |
| "One reason for CSOM recurrence might be surgery failure." | 1.56 | Chronic Suppurative Otitis Media: A Case Report. ( Eslami, G; Ghalavand, Z; Kodori, M; Tabriz, MS; Taheri, M; Yazdi, AK; Yazdi, MMK, 2020) |
| "The elective treatment for acute pouchitis is antibiotics." | 1.56 | Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment. ( Barreiro-de Acosta, M; Beltrán, B; Chaparro, M; Espín, E; Ferrer Bradley, I; Gisbert, JP; Guarner, F; Gutiérrez, A; Marín-Jimenez, I; Nos, P; Rodríguez-Lago, I, 2020) |
| "Rhinoscleroma is a chronic infectious disease that is endemic in certain poor areas of the world." | 1.48 | Rhinoscleroma: a chronic infectious disease of poor areas with characteristic histological features - report of a series of six cases. ( Ben Mansour, N; Chbani, L; Efared, B; El Fatemi, H; Gabrielle, AE; Hammas, N, 2018) |
| "Median time to first recurrence was 60 days (range 14-197)." | 1.46 | Recurrent otorrhea in chronic suppurative otitis media: is biofilm the missing link? ( Bjarnsholt, T; Eickhardt-Sørensen, SR; Homøe, P; Jensen, RG; Johansen, HK, 2017) |
| "Chronic endometritis was found in one-third of infertile women with RIF." | 1.46 | Live birth rate following oral antibiotic treatment for chronic endometritis in infertile women with repeated implantation failure. ( Ishikawa, T; Kitaya, K; Matsubayashi, H; Nishiyama, R; Takaya, Y; Takeuchi, T; Yamaguchi, K, 2017) |
| " Lead optimization resulted in the identification of potent compounds with improved oral bioavailability and reduced cardiac ion channel liability." | 1.40 | Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis. ( Achar, V; Arora, U; Awasthy, D; Bharath, S; Bheemarao, U; Chinnapattu, M; Coulson, M; de Sousa, SM; Ganguly, S; Gaonkar, S; Ghosh, A; Hameed P, S; Hoffner, S; Humnabadkar, V; Kaur, P; Kumar K N, M; Kumar, CN; Madhavapeddi, P; Manjrekar, P; Menasinakai, S; Mukherjee, K; Nandishaiah, R; Narayan, C; Panduga, V; Patil, V; Puttur, J; Raichurkar, A; Ramya, VK; Reddy, J; Rudrapatana, S; Sambandamurthy, VK; Shanbhag, G; Sharma, S; Sharma, U; Shinde, V; Solapure, S; Waterson, D; Werngren, J, 2014) |
| "This study evaluated the incidence and treatment of pouchitis in Japanese ulcerative colitis patients." | 1.39 | Clinical features and management of pouchitis in Japanese ulcerative colitis patients. ( Bando, T; Ikeuchi, H; Matsuoka, H; Takesue, Y; Tomita, N; Uchino, M, 2013) |
| "The antibiotic treatment rate of chronic bacterial prostatitis (CBP) is low, and long-term administration can result in adverse events and bacterial resistance." | 1.38 | Preventive effect of selenium on chronic bacterial prostatitis. ( Cho, YH; Ha, US; Kim, HW; Kim, SJ; Lee, SJ; Woo, JC; Yoon, BI, 2012) |
| "Levofloxacin was the most potent antibiotic against all cystic fibrosis isolates tested, with MIC(90)s ranging from 8 to 32 microg/ml." | 1.36 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. ( Burns, JL; Dudley, MN; Griffith, DC; King, P; Lomovskaya, O, 2010) |
| "Ciprofloxacin-resistance was found in 4% of isolates." | 1.35 | Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. ( Hansen, CR; Høiby, N; Pressler, T, 2008) |
| "Chloramphenicol was effective against most of the Gram-positive organisms." | 1.35 | Clinicobacteriological study of chronic dacryocystitis in adults. ( Banerjee, AR; Biswas, MC; Kundu, PK; Mandal, R; Mondal, A; Sasmal, NK, 2008) |
| "Bacterial prostatitis is documented at a very low prevalence (7-13% of prostatitis overall considered) due to either reduced utilization of viral and bacteriological tests (Meares test, urethral swab, bacterial and viral PCR) or to the possibility that individual patients show a scarce expression of bacterial disease in biological fluids, because of intraglandular biofilm presence, with subsequent spreading of the sole plankton microrganisms." | 1.35 | [Chronic prostatitis and biofilm]. ( Bartoletti, R; Cai, T, 2009) |
| "We report a chronic case of pulmonary tuberculosis in a Malagasy citizen from Antsohihy (West of Madagascar), who was infected with a multi-drug resistant Mycobacterium bovis strain." | 1.32 | [A case of pulmonary multiresistant Mycobacterium bovis tuberculosis in Madagascar]. ( Andrianasolo, D; Ramarokoto, H; Ramaroson, F; Rasolofo Razanamparany, V; Rasolonavalona, T; Ratsimba, L; Razafitsiarovana, I; Vincent, V, 2003) |
| "Ciprofloxacin resistance has increased, while Ceftazidime susceptibility is unchanged (> 90 %)." | 1.31 | [Current therapeutical management, new antibiotics and treatment of Pseudomonas aeruginosa in bacterial ENT-infections]. ( Elies, W, 2002) |
| " This new dosage regimen can be adopted as an optimal dosage for ototopical application of ciprofloxacin in chronic suppurative otitis media." | 1.30 | A new dosage regimen for topical application of ciprofloxacin in the management of chronic suppurative otitis media. ( Altuntas, A; Arda, HN; Aslan, A; Nalca, Y; Titiz, A, 1998) |
| "The basic mechanisms underlying reactive arthritis and specifically the joint injury that follows intra-articular Chlamydia trachomatis infection have not been defined." | 1.30 | Synoviocyte-packaged Chlamydia trachomatis induces a chronic aseptic arthritis. ( Chiu, B; Inman, RD, 1998) |
| "The effect of renal function on the bioavailability of ciprofloxacin was studied in 21 subjects with measured creatinine clearances ranging from 0 to 8." | 1.28 | Effect of renal function on the bioavailability of ciprofloxacin. ( Drusano, GL; Forrest, A; Plaisance, KI; Standiford, HC; Weir, MR, 1990) |
| "Ciprofloxacin was tested in the acute and chronic experimental E." | 1.27 | [Ciprofloxacin and cefotaxim: pharmacokinetic and therapeutic effectiveness in E. coli pyelonephritis in rats]. ( Boness, J; Marre, R; Schulz, E; Tietgen, K, 1986) |
| "The osteomyelitis was secondary to trauma in 12 patients, joint replacement in six, previous acute hematogenous infection in two and osteotomy in one." | 1.27 | Treatment of chronic osteomyelitis with ciprofloxacin. ( Mulier, JC; Stuyck, J; Verbist, L, 1987) |
| " An oral dose of 500 mg every 12 h was administered and both the clinical response and the pharmacokinetic profile were investigated." | 1.27 | Ciprofloxacin: multiple-dose pharmacokinetic and clinical results in patients with hypercrinic bronchopulmonary diseases. ( Braga, PC; Cortelazzi, R; Cosentina, R; Fraschini, F; Odero, A; Salvini, P; Scaglione, F; Scarpazza, G; Trazzi, R, 1987) |
| "Ciprofloxacin was well tolerated and effective in most of the ambulatory patients with refractory Gram-negative bacillary infection." | 1.27 | Oral ciprofloxacin in refractory gram-negative bacillary infections. ( Bryant, RE; Hartstein, AI, 1987) |
| " Depending on renal function the dosage varied from 100 mg once daily to 250 mg twice daily." | 1.27 | The efficacy and safety of ciprofloxacin in the treatment of chronic Pseudomonas aeruginosa urinary tract infection. ( Brown, EM; Morris, R; Stephenson, TP, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (10.38) | 18.7374 |
| 1990's | 74 (34.91) | 18.2507 |
| 2000's | 76 (35.85) | 29.6817 |
| 2010's | 32 (15.09) | 24.3611 |
| 2020's | 8 (3.77) | 2.80 |
| Authors | Studies |
|---|---|
| King, P | 1 |
| Lomovskaya, O | 1 |
| Griffith, DC | 1 |
| Burns, JL | 1 |
| Dudley, MN | 1 |
| Hameed P, S | 1 |
| Patil, V | 1 |
| Solapure, S | 1 |
| Sharma, U | 1 |
| Madhavapeddi, P | 1 |
| Raichurkar, A | 1 |
| Chinnapattu, M | 1 |
| Manjrekar, P | 1 |
| Shanbhag, G | 1 |
| Puttur, J | 1 |
| Shinde, V | 1 |
| Menasinakai, S | 1 |
| Rudrapatana, S | 1 |
| Achar, V | 1 |
| Awasthy, D | 1 |
| Nandishaiah, R | 1 |
| Humnabadkar, V | 1 |
| Ghosh, A | 1 |
| Narayan, C | 1 |
| Ramya, VK | 1 |
| Kaur, P | 1 |
| Sharma, S | 1 |
| Werngren, J | 1 |
| Hoffner, S | 1 |
| Panduga, V | 1 |
| Kumar, CN | 1 |
| Reddy, J | 1 |
| Kumar K N, M | 1 |
| Ganguly, S | 1 |
| Bharath, S | 1 |
| Bheemarao, U | 1 |
| Mukherjee, K | 1 |
| Arora, U | 1 |
| Gaonkar, S | 1 |
| Coulson, M | 1 |
| Waterson, D | 1 |
| Sambandamurthy, VK | 1 |
| de Sousa, SM | 1 |
| Kaźmierczak, W | 1 |
| Janiak-Kiszka, J | 1 |
| Budzyńska, A | 1 |
| Nowaczewska, M | 1 |
| Kaźmierczak, H | 1 |
| Gospodarek-Komkowska, E | 1 |
| Orabi, NA | 3 |
| Behnke, J | 3 |
| Reyes, C | 3 |
| Ramadan, HH | 3 |
| Makary, CA | 3 |
| Travis, S | 1 |
| Silverberg, MS | 1 |
| Danese, S | 1 |
| Gionchetti, P | 3 |
| Löwenberg, M | 1 |
| Jairath, V | 1 |
| Feagan, BG | 1 |
| Bressler, B | 1 |
| Ferrante, M | 1 |
| Hart, A | 1 |
| Lindner, D | 1 |
| Escher, A | 1 |
| Jones, S | 1 |
| Shen, B | 2 |
| Lim, DJ | 1 |
| McCormick, J | 1 |
| Skinner, D | 1 |
| Zhang, S | 1 |
| Elder, JB | 1 |
| McLemore, JG | 1 |
| Allen, M | 1 |
| West, JM | 1 |
| Grayson, JW | 1 |
| Rowe, SM | 1 |
| Woodworth, BA | 1 |
| Cho, DY | 1 |
| Yazdi, MMK | 1 |
| Ghalavand, Z | 1 |
| Yazdi, AK | 1 |
| Kodori, M | 1 |
| Taheri, M | 1 |
| Tabriz, MS | 1 |
| Eslami, G | 1 |
| Barreiro-de Acosta, M | 1 |
| Marín-Jimenez, I | 1 |
| Rodríguez-Lago, I | 1 |
| Guarner, F | 1 |
| Espín, E | 1 |
| Ferrer Bradley, I | 1 |
| Gutiérrez, A | 1 |
| Beltrán, B | 1 |
| Chaparro, M | 1 |
| Gisbert, JP | 1 |
| Nos, P | 1 |
| Bhutta, MF | 1 |
| Head, K | 1 |
| Chong, LY | 1 |
| Daw, J | 1 |
| Schilder, AG | 1 |
| Burton, MJ | 1 |
| Brennan-Jones, CG | 1 |
| Efared, B | 1 |
| Hammas, N | 1 |
| Gabrielle, AE | 1 |
| Ben Mansour, N | 1 |
| El Fatemi, H | 1 |
| Chbani, L | 1 |
| Jensen, RG | 1 |
| Johansen, HK | 1 |
| Bjarnsholt, T | 1 |
| Eickhardt-Sørensen, SR | 1 |
| Homøe, P | 1 |
| Kitaya, K | 1 |
| Matsubayashi, H | 1 |
| Takaya, Y | 1 |
| Nishiyama, R | 1 |
| Yamaguchi, K | 1 |
| Takeuchi, T | 1 |
| Ishikawa, T | 1 |
| Loo, CY | 1 |
| Lee, WH | 1 |
| Lauretani, G | 1 |
| Scalia, S | 1 |
| Cipolla, D | 1 |
| Traini, D | 1 |
| Young, P | 1 |
| Ong, HX | 1 |
| Valdes, C | 1 |
| Bustos, G | 1 |
| Martinez, JL | 1 |
| Laurido, C | 1 |
| Laulund, ASB | 1 |
| Trøstrup, H | 1 |
| Lerche, CJ | 1 |
| Thomsen, K | 1 |
| Christophersen, L | 1 |
| Calum, H | 1 |
| Høiby, N | 6 |
| Moser, C | 1 |
| Molla, R | 1 |
| Tiruneh, M | 1 |
| Abebe, W | 1 |
| Moges, F | 1 |
| Pawar, V | 1 |
| Srivastava, R | 1 |
| Pence, MA | 1 |
| Sharon, J | 1 |
| McElvania Tekippe, E | 1 |
| Pakalniskis, BL | 1 |
| Ford, BA | 1 |
| Burnham, CA | 1 |
| Sisto, F | 1 |
| Bonomi, A | 1 |
| Cavicchini, L | 1 |
| Coccè, V | 1 |
| Scaltrito, MM | 1 |
| Bondiolotti, G | 1 |
| Alessandri, G | 1 |
| Parati, E | 1 |
| Pessina, A | 1 |
| Choe, HS | 1 |
| Lee, SJ | 4 |
| Han, CH | 2 |
| Shim, BS | 1 |
| Cho, YH | 3 |
| López, E | 1 |
| Domenech, A | 1 |
| Ferrándiz, MJ | 1 |
| Frias, MJ | 1 |
| Ardanuy, C | 1 |
| Ramirez, M | 1 |
| García, E | 1 |
| Liñares, J | 1 |
| de la Campa, AG | 1 |
| Lea, J | 1 |
| Conlin, AE | 1 |
| Sekirov, I | 1 |
| Restelli, V | 1 |
| Ayakar, KG | 1 |
| Turnbull, L | 1 |
| Doyle, P | 1 |
| Noble, M | 1 |
| Rennie, R | 1 |
| Schreiber, WE | 1 |
| Westerberg, BD | 1 |
| Samarei, R | 1 |
| Park, SH | 1 |
| Ryu, JK | 2 |
| Choo, GY | 1 |
| Chung, YG | 1 |
| Seong, DH | 1 |
| Kim, CH | 1 |
| Choe, WS | 1 |
| Ryu, DS | 1 |
| Hyun, IY | 1 |
| Suh, JK | 3 |
| Langan, KM | 1 |
| Kotsimbos, T | 1 |
| Peleg, AY | 1 |
| Park, MH | 1 |
| Kim, SY | 1 |
| Roh, EY | 1 |
| Lee, HS | 1 |
| Leach, A | 1 |
| Wood, Y | 1 |
| Gadil, E | 1 |
| Stubbs, E | 1 |
| Morris, P | 1 |
| Hansen, CR | 1 |
| Pressler, T | 2 |
| Mandal, R | 1 |
| Banerjee, AR | 1 |
| Biswas, MC | 1 |
| Mondal, A | 1 |
| Kundu, PK | 1 |
| Sasmal, NK | 1 |
| Cole, LK | 1 |
| Papich, MG | 1 |
| Kwochka, KW | 1 |
| Hillier, A | 1 |
| Smeak, DD | 1 |
| Lehman, AM | 1 |
| Eisele, S | 1 |
| Garbe, E | 1 |
| Zeitz, M | 1 |
| Schneider, T | 1 |
| Somasundaram, R | 1 |
| Braccini, G | 1 |
| Festini, F | 1 |
| Boni, V | 1 |
| Neri, AS | 1 |
| Galici, V | 1 |
| Campana, S | 1 |
| Zavataro, L | 1 |
| Trevisan, F | 1 |
| Braggion, C | 1 |
| Taccetti, G | 1 |
| Kanellakopoulou, K | 2 |
| Giannitsioti, E | 1 |
| Papadopoulos, A | 2 |
| Athanassia, S | 1 |
| Giamarellos-Bourboulis, EJ | 1 |
| Giamarellou, H | 4 |
| Kapusuz, Z | 1 |
| Keles, E | 1 |
| Alpay, HC | 1 |
| Karlidag, T | 1 |
| Kaygusuz, I | 1 |
| Uzunlar, AK | 1 |
| Orhan, I | 1 |
| Yalcin, S | 1 |
| Bartoletti, R | 1 |
| Cai, T | 1 |
| Guss, J | 1 |
| Abuzeid, WM | 1 |
| Doghramji, L | 1 |
| Edelstein, PH | 1 |
| Chiu, AG | 1 |
| Weckwerth, PH | 1 |
| de Magalhães Lopes, CA | 1 |
| Duarte, MA | 1 |
| Weckwerth, AC | 1 |
| Martins, CH | 1 |
| Neto, DL | 1 |
| de Aguiar, HF | 1 |
| Turroni, S | 1 |
| Vitali, B | 1 |
| Candela, M | 1 |
| Rizzello, F | 2 |
| Campieri, M | 2 |
| Brigidi, P | 2 |
| Geiss Steiner, J | 1 |
| Trüeb, RM | 1 |
| Kerl, K | 1 |
| Mühleisen, B | 1 |
| French, LE | 1 |
| Hofbauer, GF | 1 |
| Donato, AD | 1 |
| Fontana, C | 1 |
| Pinto, R | 1 |
| Beltrutti, D | 1 |
| Pinto, G | 1 |
| Fusconi, M | 1 |
| Chiarini, F | 1 |
| Taddei, AR | 1 |
| De Virgilio, A | 1 |
| Gallinelli, C | 1 |
| Conte, M | 1 |
| De Vincentiis, M | 1 |
| Harangi, M | 1 |
| Kovács, T | 1 |
| Rákóczi, É | 1 |
| Rejto, L | 1 |
| Mikó, L | 1 |
| Tóth, L | 1 |
| Szucs, G | 1 |
| Galuska, L | 1 |
| Paragh, G | 1 |
| Magri, V | 1 |
| Montanari, E | 1 |
| Škerk, V | 2 |
| Markotić, A | 1 |
| Marras, E | 1 |
| Restelli, A | 1 |
| Naber, KG | 3 |
| Perletti, G | 1 |
| Kim, HW | 1 |
| Ha, US | 1 |
| Woo, JC | 1 |
| Kim, SJ | 1 |
| Yoon, BI | 1 |
| Akhaddar, A | 1 |
| Boulahroud, O | 1 |
| Boucetta, M | 1 |
| Malamitsi, J | 1 |
| Vezyrgianni, A | 1 |
| Dalianis, K | 1 |
| Boutsikou, M | 1 |
| Loock, JW | 1 |
| Uchino, M | 1 |
| Ikeuchi, H | 1 |
| Matsuoka, H | 1 |
| Bando, T | 1 |
| Takesue, Y | 1 |
| Tomita, N | 1 |
| Antonela Antoniu, S | 1 |
| Afolabi, OA | 1 |
| Salaudeen, AG | 1 |
| Ologe, FE | 1 |
| Nwabuisi, C | 1 |
| Nwawolo, CC | 1 |
| Bakker-Woudenberg, IA | 1 |
| ten Kate, MT | 1 |
| Guo, L | 1 |
| Working, P | 1 |
| Mouton, JW | 1 |
| Kurzer, E | 1 |
| Kaplan, S | 1 |
| Deitmer, T | 1 |
| Bataille, L | 1 |
| Rahier, J | 1 |
| Geubel, A | 1 |
| Zomorrodi, A | 1 |
| Wald, ER | 1 |
| Yang, Y | 1 |
| Gong, S | 1 |
| Liu, Y | 1 |
| Duĭsenova, AK | 1 |
| Kurmanova, KB | 1 |
| Kurmanova, GM | 1 |
| Schönwald, S | 1 |
| Krhen, I | 1 |
| Banaszak, A | 1 |
| Begovac, J | 1 |
| Strugar, J | 1 |
| Strapac, Z | 1 |
| Vrsalovic, R | 1 |
| Vukovic, J | 1 |
| Tomas, M | 1 |
| Couzos, S | 1 |
| Lea, T | 1 |
| Mueller, R | 1 |
| Murray, R | 1 |
| Culbong, M | 1 |
| Yli-Kerttula, T | 1 |
| Luukkainen, R | 1 |
| Yli-Kerttula, U | 1 |
| Möttönen, T | 1 |
| Hakola, M | 1 |
| Korpela, M | 1 |
| Sanila, M | 1 |
| Uksila, J | 1 |
| Toivanen, A | 1 |
| Cao, W | 1 |
| Liu, L | 1 |
| Tong, MH | 1 |
| Lee, SM | 1 |
| Seong, DW | 1 |
| Kim, S | 2 |
| Choe, W | 2 |
| Moon, Y | 1 |
| Pai, SH | 1 |
| Bundrick, W | 1 |
| Heron, SP | 1 |
| Ray, P | 1 |
| Schiff, WM | 1 |
| Tennenberg, AM | 2 |
| Wiesinger, BA | 1 |
| Wright, PA | 1 |
| Wu, SC | 2 |
| Zadeikis, N | 1 |
| Kahn, JB | 2 |
| Kamanin, EI | 1 |
| Trofimov, AE | 1 |
| Jaya, C | 1 |
| Job, A | 1 |
| Mathai, E | 1 |
| Antonisamy, B | 1 |
| Dugdale, AE | 1 |
| Lee, TW | 1 |
| Brownlee, KG | 1 |
| Denton, M | 2 |
| Littlewood, JM | 1 |
| Conway, SP | 2 |
| Brewster, DR | 1 |
| Kidd, JD | 1 |
| Jang, CH | 1 |
| Park, SY | 1 |
| Gaur, S | 1 |
| Trayner, E | 1 |
| Aish, L | 1 |
| Weinstein, R | 1 |
| Dignass, AU | 1 |
| Herrlinger, K | 1 |
| Schölmerich, J | 2 |
| Kadry, AA | 1 |
| Al-Suwayeh, SA | 1 |
| Abd-Allah, AR | 1 |
| Bayomi, MA | 1 |
| Alexander, RB | 2 |
| Propert, KJ | 2 |
| Schaeffer, AJ | 3 |
| Landis, JR | 2 |
| Nickel, JC | 2 |
| O'Leary, MP | 1 |
| Pontari, MA | 1 |
| McNaughton-Collins, M | 1 |
| Shoskes, DA | 1 |
| Comiter, CV | 1 |
| Datta, NS | 1 |
| Fowler, JE | 1 |
| Nadler, RB | 1 |
| Zeitlin, SI | 1 |
| Knauss, JS | 1 |
| Wang, Y | 1 |
| Kusek, JW | 2 |
| Nyberg, LM | 2 |
| Litwin, MS | 2 |
| Weidner, W | 2 |
| Tözüm, TF | 1 |
| Yildirim, A | 1 |
| Cağlayan, F | 1 |
| Dinçel, A | 1 |
| Bozkurt, A | 1 |
| Ramarokoto, H | 1 |
| Andrianasolo, D | 1 |
| Rasolonavalona, T | 1 |
| Ramaroson, F | 1 |
| Razafitsiarovana, I | 1 |
| Vincent, V | 1 |
| Ratsimba, L | 1 |
| Rasolofo Razanamparany, V | 1 |
| Macfadyen, C | 2 |
| Gamble, C | 2 |
| Garner, P | 2 |
| Macharia, I | 2 |
| Mackenzie, I | 2 |
| Mugwe, P | 2 |
| Oburra, H | 2 |
| Otwombe, K | 2 |
| Taylor, S | 2 |
| Williamson, P | 2 |
| Kumar, VV | 1 |
| Gaughan, J | 1 |
| Isaacson, G | 1 |
| Szeremeta, W | 1 |
| Bezrukova, IV | 1 |
| Dmitrieva, NA | 1 |
| Gerchikov, LN | 1 |
| Abdelrazeq, AS | 1 |
| Kelly, SM | 1 |
| Lund, JN | 1 |
| Leveson, SH | 1 |
| Nadesalingam, K | 1 |
| Lee, YS | 1 |
| Kang, SH | 1 |
| Kim, SW | 1 |
| Shin, OR | 1 |
| Sim, YC | 1 |
| Paszkowska, M | 1 |
| Niemir, ZI | 1 |
| Nowak, A | 1 |
| Czekalski, S | 1 |
| Frederiksen, B | 2 |
| Tezel, A | 1 |
| Yucel, O | 1 |
| Orbak, R | 1 |
| Kara, C | 1 |
| Kavrut, F | 1 |
| Yagiz, H | 1 |
| Sahin, T | 1 |
| Loendersloot, E | 1 |
| Branolte, JH | 1 |
| Battikhi, MN | 1 |
| Ismail, H | 1 |
| Battikhi, Q | 1 |
| Olapade-Olaopa, EO | 1 |
| Adebayo, SA | 1 |
| García-Alvarez, F | 2 |
| Monzón, M | 2 |
| Grasa, JM | 1 |
| Laclériga, A | 2 |
| Amorena, B | 2 |
| García-Alvarez, I | 1 |
| Navarro-Zorraquino, M | 1 |
| Alvarez, FG | 1 |
| Bukharin, OV | 1 |
| Gritsenko, VA | 1 |
| Tret'iakov, AA | 1 |
| Chernikov, DA | 1 |
| Fazio, VW | 1 |
| Remzi, FH | 1 |
| Bennett, AE | 1 |
| Lopez, R | 1 |
| Brzezinski, A | 1 |
| Oikonomou, I | 1 |
| Sherman, KK | 1 |
| Lashner, BA | 1 |
| Navarro-Llavat, M | 1 |
| Domènech, E | 1 |
| Masnou, H | 1 |
| Ojanguren, I | 1 |
| Mañosa, M | 1 |
| Lorenzo-Zúñiga, V | 1 |
| Boix, J | 1 |
| Gassull, MA | 1 |
| Kulovac, B | 1 |
| Aganović, D | 1 |
| Prcić, A | 1 |
| Hadziosmanović, O | 1 |
| Kertes, P | 1 |
| Goncalves, F | 1 |
| Stefancik, J | 1 |
| Dubravicky, J | 1 |
| Hladik, M | 1 |
| Breza, J | 1 |
| Lorente, J | 1 |
| Sabater, F | 1 |
| Maristany, M | 1 |
| Jiménez, R | 1 |
| Menem, J | 1 |
| Viñas, J | 1 |
| Quesada, P | 1 |
| Traserra, J | 1 |
| Dicenta, M | 1 |
| Abelló, P | 1 |
| Tutkun, A | 2 |
| Ozagar, A | 2 |
| Koç, A | 2 |
| Batman, C | 1 |
| Uneri, C | 1 |
| Sehitoglu, MA | 2 |
| Rautelin, H | 1 |
| Hänninen, ML | 1 |
| Sivonen, A | 1 |
| Turunen, U | 1 |
| Valtonen, V | 1 |
| Tsourvakas, S | 1 |
| Hatzigrigoris, P | 1 |
| Tsibinos, A | 1 |
| Dounis, E | 1 |
| Force, RW | 1 |
| Hart, MC | 1 |
| Plummer, SA | 1 |
| Powell, DA | 1 |
| Nahata, MC | 1 |
| Scaglione, F | 2 |
| Scamazzo, F | 1 |
| Arcidiacono, MM | 1 |
| Cogo, R | 1 |
| Monzani, GP | 1 |
| Fraschini, F | 2 |
| Legent, F | 2 |
| Bordure, P | 2 |
| Beauvillain, C | 2 |
| Berche, P | 3 |
| Fombeur, JP | 3 |
| Barrault, S | 2 |
| Koubbi, G | 2 |
| Laurier, JN | 2 |
| Ebbo, D | 2 |
| Lecomte, F | 2 |
| Sorrel, N | 2 |
| Dobler, S | 2 |
| Doganov, N | 1 |
| Iarŭkov, A | 1 |
| Karag'ozov, I | 1 |
| Bozhilov, D | 1 |
| Diavolov, V | 1 |
| Sheldon, CD | 1 |
| Assoufi, BK | 1 |
| Hodson, ME | 1 |
| Houston, S | 1 |
| Yamaguti, A | 1 |
| Trevisanello, C | 1 |
| Lobo, IM | 1 |
| Carvalho, MC | 1 |
| Bortoletto, ML | 1 |
| Silva, ML | 1 |
| Brasil Filho, R | 1 |
| Levi, GC | 1 |
| Mendonça, JS | 1 |
| Barriere, SL | 1 |
| Hindler, JA | 1 |
| García Rodríguez, JA | 1 |
| García Sánchez, JE | 1 |
| García García, MI | 1 |
| García Sánchez, E | 1 |
| Muñoz Bellido, JL | 1 |
| Ramos Macías, A | 1 |
| Vazquez, C | 1 |
| Municio, M | 1 |
| Corera, M | 1 |
| Gaztelurrutia, L | 1 |
| Sojo, A | 1 |
| Vitoria, JC | 1 |
| Sturniolo, G | 1 |
| Ricciardi, F | 1 |
| Ruggeri, P | 1 |
| Costantino, G | 1 |
| Pellicanò, GF | 1 |
| Bertuccio, O | 1 |
| La Rosá, F | 1 |
| Wise, JB | 1 |
| Gaillot, O | 1 |
| Nouvet, G | 1 |
| Benmessaoud, K | 1 |
| Cazzola, M | 1 |
| Vinciguerra, A | 1 |
| Beghi, GF | 1 |
| Paizis, G | 1 |
| Giura, R | 1 |
| Madonini, V | 1 |
| Fiorentini, F | 1 |
| Consigli, GF | 1 |
| Tonna, M | 1 |
| Casalini, A | 1 |
| Riley, UB | 1 |
| Bignardi, G | 1 |
| Goldberg, L | 1 |
| Johnson, AP | 1 |
| Holmes, B | 1 |
| Altuntas, A | 2 |
| Aslan, A | 2 |
| Eren, N | 1 |
| Unal, A | 1 |
| Nalca, Y | 2 |
| Sato, A | 1 |
| Kitazawa, H | 1 |
| Hayakawa, H | 1 |
| Chida, K | 1 |
| Iwata, M | 1 |
| Koch, C | 3 |
| Gehanno, P | 1 |
| Chuchalin, AG | 1 |
| Novikov, IuK | 1 |
| Avdeev, SN | 1 |
| Belevskiĭ, AS | 1 |
| Bakalova, LA | 1 |
| Akovbian, VA | 1 |
| Bednova, VN | 1 |
| Ciprut, A | 1 |
| Akdaş, F | 1 |
| Fradis, M | 2 |
| Brodsky, A | 1 |
| Ben-David, J | 2 |
| Srugo, I | 2 |
| Larboni, J | 2 |
| Podoshin, L | 2 |
| Rissing, JP | 1 |
| Grossman, R | 2 |
| Mukherjee, J | 3 |
| Vaughan, D | 3 |
| Eastwood, C | 1 |
| Cook, R | 1 |
| LaForge, J | 1 |
| Lampron, N | 2 |
| Chodosh, S | 4 |
| Lakshminarayan, S | 1 |
| Swarz, H | 1 |
| Breisch, S | 1 |
| Komarova, VP | 1 |
| Belousov, IuB | 1 |
| Sokolov, AV | 1 |
| Tishchenkova, IF | 1 |
| Efremenkova, OV | 1 |
| Ng, ET | 2 |
| Cook, RJ | 2 |
| Brodzki, A | 1 |
| Titiz, A | 1 |
| Arda, HN | 1 |
| Zuck, P | 1 |
| Weber, P | 1 |
| Dohar, JE | 1 |
| Alper, CM | 1 |
| Rose, EA | 1 |
| Doyle, WJ | 1 |
| Casselbrant, ML | 1 |
| Kenna, MA | 1 |
| Bluestone, CD | 1 |
| McCarty, J | 1 |
| Farkas, S | 1 |
| Drehobl, M | 1 |
| Tosiello, R | 1 |
| Shan, M | 2 |
| Aneiro, L | 1 |
| Kowalsky, S | 2 |
| Schreurs, A | 1 |
| Siami, G | 1 |
| Barkman, HW | 1 |
| Anzueto, A | 1 |
| Moesker, H | 1 |
| Stack, T | 1 |
| Fontanel, JP | 1 |
| Inman, RD | 2 |
| Chiu, B | 1 |
| Kiris, M | 1 |
| Berktas, M | 1 |
| Egeli, E | 1 |
| Kutluhan, A | 1 |
| Destache, CJ | 1 |
| Dewan, N | 1 |
| O'Donohue, WJ | 1 |
| Campbell, JC | 1 |
| Angelillo, VA | 1 |
| Venturi, A | 1 |
| Ugolini, F | 1 |
| Rossi, M | 1 |
| Johansson, R | 1 |
| Ferrieri, A | 1 |
| Poggioli, G | 1 |
| Greenberg, RN | 1 |
| Newman, MT | 1 |
| Shariaty, S | 1 |
| Pectol, RW | 1 |
| Begg, EJ | 1 |
| Robson, RA | 1 |
| Saunders, DA | 1 |
| Graham, GG | 1 |
| Buttimore, RC | 1 |
| Neill, AM | 1 |
| Town, GI | 1 |
| Torrance, G | 1 |
| Walker, V | 1 |
| La Forge, J | 1 |
| Busch, W | 1 |
| Focht, J | 1 |
| Hans, W | 1 |
| Gross, V | 1 |
| Falk, W | 1 |
| Boyanova, L | 1 |
| Stancheva, I | 1 |
| Spassova, Z | 1 |
| Katzarov, N | 1 |
| Mitov, I | 1 |
| Koumanova, R | 1 |
| Verdier, RI | 1 |
| Fitzgerald, DW | 1 |
| Johnson, WD | 1 |
| Pape, JW | 1 |
| Miró, N | 1 |
| Stone, M | 1 |
| Kuczkowski, J | 1 |
| Samet, A | 1 |
| Brzoznowski, W | 1 |
| Sonmezoglu, K | 1 |
| Sonmezoglu, M | 1 |
| Halac, M | 1 |
| Akgün, I | 1 |
| Türkmen, C | 1 |
| Onsel, C | 1 |
| Kanmaz, B | 1 |
| Solanki, K | 1 |
| Britton, KE | 1 |
| Uslu, I | 1 |
| Gracia, E | 1 |
| Leiva, J | 1 |
| Oteiza, C | 1 |
| Lelièvre, G | 1 |
| Baiulescu, M | 1 |
| Hannon, PR | 1 |
| Marcinak, JF | 1 |
| Janda, WM | 1 |
| Schreckenberger, PC | 1 |
| Elies, W | 1 |
| Banky, JP | 1 |
| Ostergaard, L | 1 |
| Spelman, D | 1 |
| Chung, MH | 1 |
| Kim, WH | 1 |
| Kan Ryu, J | 1 |
| Jin Kang, K | 1 |
| Grassi, C | 1 |
| Salvatori, E | 1 |
| Rosignoli, MT | 1 |
| Dionisio, P | 1 |
| Legnani, D | 1 |
| Lombardo, VM | 1 |
| Negretto, GG | 1 |
| Beghi, G | 1 |
| Caratozzolo, O | 1 |
| Lang, R | 1 |
| Goshen, S | 1 |
| Raas-Rothschild, A | 1 |
| Raz, A | 1 |
| Ophir, D | 1 |
| Wolach, B | 1 |
| Berger, I | 1 |
| Ford, TC | 1 |
| Teramoto, S | 1 |
| Fukuchi, Y | 1 |
| Nagase, T | 1 |
| Orimo, H | 1 |
| Esposito, S | 3 |
| Noviello, S | 1 |
| D'Errico, G | 2 |
| Montanaro, C | 2 |
| Valerius, NH | 1 |
| Hurley, JC | 1 |
| Louis, WJ | 1 |
| Tosolini, FA | 1 |
| Carlin, JB | 1 |
| Schiefer, HG | 1 |
| Brähler, E | 1 |
| Levenson, MJ | 1 |
| Parisier, SC | 1 |
| Dolitsky, J | 1 |
| Bindra, G | 1 |
| Yoshida, M | 1 |
| Watanabe, K | 1 |
| Tamaru, N | 1 |
| Ishibashi, T | 1 |
| Takamoto, M | 1 |
| Yamada, H | 1 |
| Katoh, O | 1 |
| Yamaguchi, T | 1 |
| Ando, M | 1 |
| Matsumoto, M | 1 |
| Kikuchi, N | 1 |
| Kawashima, T | 1 |
| Yamagishi, F | 1 |
| Suzuki, K | 1 |
| Yasuda, J | 1 |
| Niijima, Y | 1 |
| Mizutani, F | 1 |
| Tabeta, H | 1 |
| Murdoch, MB | 1 |
| Peterson, LR | 1 |
| Aagaard, J | 1 |
| Gasser, T | 1 |
| Rhodes, P | 1 |
| Madsen, PO | 1 |
| Gentry, LO | 1 |
| Rodriguez, GG | 1 |
| Montay, G | 1 |
| Gaillot, J | 1 |
| Mader, JT | 1 |
| Cantrell, JS | 1 |
| Calhoun, J | 1 |
| Read, RC | 1 |
| Barry, RE | 1 |
| Dworkin, R | 1 |
| Modin, G | 1 |
| Kunz, S | 1 |
| Rich, R | 1 |
| Zak, O | 1 |
| Sande, M | 1 |
| Plaisance, KI | 1 |
| Drusano, GL | 1 |
| Forrest, A | 1 |
| Weir, MR | 1 |
| Standiford, HC | 1 |
| Childs, SJ | 1 |
| Piccirillo, JF | 1 |
| Parnes, SM | 1 |
| Schmidt, EW | 1 |
| Zimmermann, I | 1 |
| Ritzerfeld, W | 1 |
| Voss, E | 1 |
| Ulmer, WT | 1 |
| Hoogkamp-Korstanje, JA | 2 |
| van Bottenburg, HA | 1 |
| van Bruggen, J | 1 |
| Davidson, JS | 1 |
| Detmar, SJ | 1 |
| de Graaf, W | 1 |
| Rijnks, J | 1 |
| Ypma, JF | 1 |
| de Zwart, DF | 1 |
| Sammalkorpi, K | 1 |
| Lähdevirta, J | 1 |
| Mäkelä, T | 1 |
| Rostila, T | 1 |
| Davies, BI | 2 |
| Maesen, FP | 2 |
| Teengs, JP | 1 |
| Baur, C | 2 |
| Van de Heyning, PH | 2 |
| Pattyn, SR | 2 |
| Valcke, HD | 2 |
| Galanakis, N | 1 |
| Dendrinos, C | 1 |
| Stefanou, J | 1 |
| Daphnis, E | 1 |
| Daikos, GK | 1 |
| Tietgen, K | 1 |
| Schulz, E | 1 |
| Boness, J | 1 |
| Marre, R | 1 |
| Hoen, MM | 1 |
| Downs, RH | 1 |
| LaBounty, GL | 1 |
| Nespeca, JA | 1 |
| Norden, CW | 1 |
| Shinners, E | 1 |
| van Caekenberghe, DL | 1 |
| Claes, J | 1 |
| Jensen, T | 1 |
| Pedersen, SS | 1 |
| Stuyck, J | 1 |
| Verbist, L | 1 |
| Mulier, JC | 1 |
| Leigh, DA | 1 |
| Emmanuel, FX | 1 |
| Petch, VJ | 1 |
| Braga, PC | 1 |
| Cosentina, R | 1 |
| Salvini, P | 1 |
| Cortelazzi, R | 1 |
| Scarpazza, G | 1 |
| Trazzi, R | 1 |
| Odero, A | 1 |
| Bryant, RE | 1 |
| Hartstein, AI | 1 |
| Galante, D | 1 |
| Barba, D | 1 |
| Giusti, G | 1 |
| Brown, EM | 1 |
| Morris, R | 1 |
| Stephenson, TP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT01843946] | 75 participants (Actual) | Observational | 2011-03-31 | Completed | |||
| A Multicenter, Double-Blind Study to Compare the Safety and Efficacy of Levofloxacin to That of Ciprofloxacin in the Treatment of Chronic Prostatitis[NCT00236808] | Phase 3 | 383 participants (Actual) | Interventional | 2000-05-31 | Completed | ||
| A Randomized Clinical Trial to Evaluate the Efficacy and Safety of 10mg Alfuzosin in the Treatment of Chronic Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS) in Recently-Diagnosed and/or Newly-Symptomatic Alpha-blocker Naïve Patients[NCT00103402] | Phase 3 | 272 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Supplementary Oral Azithromycin in Treatment of Intermittent Pseudomonas Aeruginosa Colonization in CF-patients With Inhaled Colistin and Oral Ciprofloxacin; Postponing Next Isolate of Pseudomonas and Prevention of Chronic Infection. A Prospective, Double[NCT00411736] | Phase 4 | 45 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| A Pilot Study of the Safety and Efficacy of AST-120 in the Treatment of Active Pouchitis[NCT00583076] | Phase 2 | 19 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Role of Doxycycline in the Management of Patients With Chronic Rhinosinusitis With Nasal Polyps[NCT05157412] | Phase 3 | 60 participants (Anticipated) | Interventional | 2022-03-01 | Not yet recruiting | ||
| A Pilot Study of the Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis[NCT00583531] | Phase 2 | 2 participants (Actual) | Interventional | 2007-03-31 | Terminated (stopped due to Lack of enrollment) | ||
| Ciprofloxacin or Tamsulosin in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: a Randomized, Double-blind Trial[NCT04552431] | Phase 2 | 196 participants (Actual) | Interventional | 1997-09-30 | Completed | ||
| Genetic Study of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)[NCT00499317] | 500 participants (Anticipated) | Observational | 2007-01-15 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For the Hospital Anxiety and Depression Scale, higher scores indicate greater anxiety and depression; range, 0 to 42. (NCT00103402)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Alfuzosin | -2.6 |
| Placebo | -1.5 |
For the International Index of Erectile Function, higher scores indicate better sexual function; range, 0 to 75. (NCT00103402)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Alfuzosin | 0.5 |
| Placebo | -0.2 |
For the Male Sexual Health Questionnaire, higher scores indicate better function with respect to erection and ejaculation and greater satisfaction with sexual life; range, 0 to 40. (NCT00103402)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Alfuzosin | 1.7 |
| Placebo | 0.6 |
For the National Institutes of Health Chronic Prostatitis Symptom Index (NIHCPSI) total score, higher scores indicate more severe symptoms and scores range from 0 to 43. The primary outcome was a decline of at least 4 from baseline to 12 weeks (NCT00103402)
Timeframe: Baseline and 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Alfuzosin | 68 |
| Placebo | 66 |
For the Medical Outcomes Study Short Form Health Survey 12 (SF-12), higher scores indicate better quality of life. Score range for both the physical and mental component summaries is 0 to 100. (NCT00103402)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Physical component | Mental component | |
| Alfuzosin | 3.0 | 4.0 |
| Placebo | 3.5 | 1.9 |
For the McGill Pain Questionnaire, higher scores indicate greater pain. Score ranges are as follows: total score, 0 to 45; sensory score, 0 to 33; affective score, 0 to 12. (NCT00103402)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Total score | Sensory score | Affective score | |
| Alfuzosin | -3.4 | -2.5 | -1.0 |
| Placebo | -3.1 | -2.3 | -0.9 |
For the National Institutes of Health Chronic Prostatitis Symptom Index (NIHCPSI), higher scores indicate more severe symptoms (for the quality-of-life score, higher scores indicate a more negative effect). Score ranges are as follows: total score, 0 to 43; pain score, 0 to 21; urinary score, 0 to 10, quality-of-life score, 0 to 12; and average pain and urgency scores, 0 to 10. (NCT00103402)
Timeframe: Baseline and12 weeks
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Total score | Pain score | Urinary score | Quality-of-life score | |
| Alfuzosin | -7.1 | -3.3 | -1.2 | -1.2 |
| Placebo | -6.5 | -3.0 | -1.0 | -1.2 |
15 reviews available for ciprofloxacin and Chronic Illness
| Article | Year |
|---|---|
Aural toilet (ear cleaning) for chronic suppurative otitis media.
Topics: Adult; Anti-Bacterial Agents; Bias; Child; Chronic Disease; Ciprofloxacin; Humans; Hygiene; Otitis M | 2020 |
Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis.
Topics: Administration, Inhalation; Administration, Oral; Anti-Bacterial Agents; Chronic Disease; Ciprofloxa | 2015 |
Ciprofloxacin-related acute severe myalgia necessitating emergency care treatment: a case report and review of the literature.
Topics: Acute Disease; Anti-Bacterial Agents; Chronic Disease; Ciprofloxacin; Emergencies; Humans; Injection | 2009 |
Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Chronic Disease; Ciprofloxacin; Clinical Trials a | 2012 |
Topical and systemic treatment for chronic suppurative otitis media.
Topics: Administration, Oral; Administration, Topical; Child; Child, Preschool; Chronic Disease; Ciprofloxac | 2002 |
Ecthyma gangrenosum: considerations in a previously healthy child.
Topics: Administration, Oral; Chronic Disease; Ciprofloxacin; Ecthyma; Female; Follow-Up Studies; Granulocyt | 2002 |
Eradication of early Pseudomonas aeruginosa infection.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Colistin; Cystic Fibro | 2005 |
Collagenous duodeno-ileo-colitis with transient IgG deficiency preceded by Yersinia enterocolitica intestinal infection: case report and review of literature.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Budesonide; Chronic Disease; Ciprofloxacin; Colitis | 2007 |
Antimicrobial therapy for chronic osteomyelitis in adults: role of the quinolones.
Topics: Adult; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Humans; Osteomyelitis; Randomized Cont | 1997 |
Recent developments in the therapy of spondyloarthropathies.
Topics: Alleles; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Monoclonal; Antirheumati | 2000 |
Chronic relapsing salmonella osteomyelitis in an immunocompetent patient: case report and literature review.
Topics: Adult; Anti-Infective Agents; Cefazolin; Ceftriaxone; Cephalosporins; Chronic Disease; Ciprofloxacin | 2002 |
Use of quinolones for the treatment of acute exacerbations of chronic bronchitis.
Topics: Acute Disease; Anti-Infective Agents; Bronchitis; Chronic Disease; Ciprofloxacin; Fluoroquinolones; | 1991 |
Pharmacokinetics of fluoroquinolones in hepatic failure.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Female; Ha | 1990 |
Ciprofloxacin in treatment of chronic bacterial prostatitis.
Topics: Chronic Disease; Ciprofloxacin; Humans; Male; Prostatitis | 1990 |
The use of fluoroquinolones in chronic otitis suppurativa.
Topics: Cholesteatoma; Chronic Disease; Ciprofloxacin; Clinical Trials as Topic; Enoxacin; Humans; Mastoidit | 1987 |
68 trials available for ciprofloxacin and Chronic Illness
| Article | Year |
|---|---|
Vedolizumab for the Treatment of Chronic Pouchitis.
Topics: Administration, Intravenous; Adult; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Chroni | 2023 |
Clinical efficacy of roxithromycin in men with chronic prostatitis/chronic pelvic pain syndrome in comparison with ciprofloxacin and aceclofenac: a prospective, randomized, multicenter pilot trial.
Topics: Adult; Chronic Disease; Ciprofloxacin; Diclofenac; Humans; Male; Pelvic Pain; Pilot Projects; Prospe | 2014 |
Comparison of local and systemic ciprofloxacin ototoxicity in the treatment of chronic media otitis.
Topics: Administration, Oral; Administration, Topical; Anti-Bacterial Agents; Audiometry; Chronic Disease; C | 2014 |
Topical ciprofloxin versus topical framycetin-gramicidin-dexamethasone in Australian aboriginal children with recently treated chronic suppurative otitis media: a randomized controlled trial.
Topics: Administration, Topical; Adolescent; Anti-Bacterial Agents; Anti-Inflammatory Agents; Australia; Chi | 2008 |
Plasma and ear tissue concentrations of enrofloxacin and its metabolite ciprofloxacin in dogs with chronic end-stage otitis externa after intravenous administration of enrofloxacin.
Topics: Animals; Anti-Bacterial Agents; Chronic Disease; Ciprofloxacin; Dog Diseases; Dogs; Dose-Response Re | 2009 |
Antibiotics and probiotics in chronic pouchitis: a comparative proteomic approach.
Topics: Anti-Bacterial Agents; Bibliometrics; Biopsy; Chronic Disease; Ciprofloxacin; Drug Therapy, Combinat | 2010 |
A randomised controlled trial of active chronic otitis media comparing courses of eardrops versus one-off topical treatments suitable for primary, secondary and tertiary healthcare settings.
Topics: Acetic Acid; Administration, Topical; Adult; Analysis of Variance; Anti-Infective Agents; Audiometry | 2012 |
Lomefloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Fluoroquinolones | 2002 |
Comparative analysis of azithromycin and ciprofloxacin in the treatment of chronic prostatitis caused by Chlamydia trachomatis.
Topics: Adolescent; Adult; Aged; Azithromycin; Chlamydia Infections; Chlamydia trachomatis; Chronic Disease; | 2003 |
Effectiveness of ototopical antibiotics for chronic suppurative otitis media in Aboriginal children: a community-based, multicentre, double-blind randomised controlled trial.
Topics: Administration, Topical; Adolescent; Anti-Infective Agents; Child; Child, Preschool; Chronic Disease | 2003 |
Effect of a three month course of ciprofloxacin on the late prognosis of reactive arthritis.
Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Arthritis, Reactive; Chronic Disease; Ciprofloxac | 2003 |
Tc-99m ciprofloxacin imaging in diagnosis of chronic bacterial prostatitis.
Topics: Adult; Aged; Bacterial Infections; Chronic Disease; Ciprofloxacin; Humans; Male; Middle Aged; Organo | 2003 |
Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study.
Topics: Adult; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Ciprofloxacin; Double-Blind Met | 2003 |
Evaluation of topical povidone-iodine in chronic suppurative otitis media.
Topics: Administration, Topical; Adolescent; Adult; Anti-Infective Agents, Local; Child; Chronic Disease; Ci | 2003 |
Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial.
Topics: Adrenergic alpha-Antagonists; Adult; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Double-B | 2004 |
Topical quinolone vs. antiseptic for treating chronic suppurative otitis media: a randomized controlled trial.
Topics: Adolescent; Anti-Infective Agents, Local; Boric Acids; Child; Child, Preschool; Chronic Disease; Cip | 2005 |
Topical quinolone vs. antiseptic for treating chronic suppurative otitis media: a randomized controlled trial.
Topics: Administration, Topical; Anti-Infective Agents; Auditory Threshold; Boric Acids; Child; Chronic Dise | 2005 |
Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; | 2005 |
Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis.
Topics: Administration, Oral; Administration, Topical; Adult; Anti-Infective Agents; Chronic Disease; Ciprof | 2007 |
Management of chronic nonbacterial prostatitis/chronic pelvic pain syndrome.
Topics: Adult; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Doxazosin; Drug Therapy, Combination; | 2007 |
Value of antibiotic therapy for bioptically proved chronic prostatitis.
Topics: Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Humans; Male; Prostate-Specific Antigen; Pros | 2008 |
[Multicenter study comparing the efficacy and tolerance of topical ciprofloxacin (0.3%) versus topical gentamicin (0.3%) in the treatment of simple, non-cholesteatomaous chronic otitis media in the suppurative phase].
Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Bacterial Agents; Aspergillus; Candida albica | 1995 |
Treatment of chronic ear disease. Topical ciprofloxacin vs topical gentamicin.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Chi-Squ | 1995 |
Topical ciprofloxacin for otorrhea after tympanostomy tube placement.
Topics: Administration, Topical; Audiometry; Child; Child, Preschool; Chronic Disease; Ciprofloxacin; Female | 1995 |
Comparative activities of pefloxacin and ciprofloxacin in the treatment of chronic respiratory tract infections.
Topics: Adult; Bacterial Infections; Bronchi; Bronchoalveolar Lavage Fluid; Chronic Disease; Ciprofloxacin; | 1995 |
Controlled prospective study of oral ciprofloxacin versus amoxycillin/clavulanic acid in chronic suppurative otitis media in adults.
Topics: Adult; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Bacterial Infections; Chronic Dis | 1994 |
Study of the efficacy and safety of ciprofloxacin in the treatment of chronic sinusitis.
Topics: Adult; Chronic Disease; Ciprofloxacin; Female; Gram-Negative Bacterial Infections; Gram-Positive Bac | 1994 |
Study of the efficacy and safety of ciprofloxacin in the treatment of chronic otitis.
Topics: Adult; Bacterial Infections; Chronic Disease; Ciprofloxacin; Earache; Female; Humans; Male; Middle A | 1994 |
A double-blind comparison of ciprofloxacin and amoxycillin/clavulanic acid in the treatment of chronic sinusitis.
Topics: Adolescent; Adult; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Bacterial Infections; | 1994 |
[The clinical study of the preparation ciprofloxacin in inflammatory gynecological diseases].
Topics: Acute Disease; Adult; Analysis of Variance; Chronic Disease; Ciprofloxacin; Endometritis; Female; Hu | 1993 |
Regular three monthly oral ciprofloxacin in adult cystic fibrosis patients infected with Pseudomonas aeruginosa.
Topics: Administration, Oral; Adult; Chronic Disease; Ciprofloxacin; Cystic Fibrosis; Double-Blind Method; D | 1993 |
Efficacy of topical ciprofloxacin in the treatment of ear infections in adults.
Topics: Administration, Topical; Adult; Bacterial Infections; Chronic Disease; Ciprofloxacin; Ear Diseases; | 1993 |
Early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis.
Topics: Adolescent; Aerosols; Bronchial Diseases; Child; Child, Preschool; Chronic Disease; Ciprofloxacin; C | 1993 |
Comparative study of efficacy and safety of ciprofloxacin and cefixime in the treatment of acute exacerbations of chronic bronchitis after first-line treatment failure. French Study Group.
Topics: Aged; Anti-Infective Agents; Bronchitis; Cefixime; Cefotaxime; Chronic Disease; Ciprofloxacin; Drug | 1995 |
Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Amoxicillin-Potassium Clavulanate Combinati | 1995 |
Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Carrier State; Child; Child, Presch | 1997 |
Multicenter study of the efficacy and safety of oral ciprofloxacin in the treatment of chronic suppurative otitis media in adults. The French Study Group.
Topics: Administration, Oral; Age Factors; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Family Pra | 1997 |
[Effectiveness of ciprofloxacin in the treatment of hospital infections of the lower respiratory tract].
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Infective Agents; Bronchiectasis; Bronchitis; Ch | 1997 |
Effects of topical otic preparations on hearing in chronic otitis media.
Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Audi | 1997 |
Chronic otitis media treated topically with ciprofloxacin or tobramycin.
Topics: Administration, Topical; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Chronic Disease; | 1997 |
A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group.
Topics: Adolescent; Adult; Anti-Infective Agents; Bronchitis; Canada; Chronic Disease; Ciprofloxacin; Cost-B | 1998 |
Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bronchitis; Bronch | 1998 |
Modeling two-state disease processes with random effects.
Topics: Anti-Infective Agents; Bronchitis; Chronic Disease; Ciprofloxacin; Epidemiologic Methods; Humans; Li | 1997 |
[Local treatment of purulent chronic otitis media with ciprofloxacin].
Topics: Administration, Topical; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Chronic Disease; | 1998 |
Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group.
Topics: Acute Disease; Adolescent; Adult; Anti-Infective Agents; Bronchitis; Cefuroxime; Cephalosporins; Chr | 1998 |
Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Bronchitis; C | 1998 |
The efficacy of topical ciprofloxacin in the treatment of chronic suppurative otitis media.
Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Infective Agents; Bacteria; Child; Child, Pre | 1998 |
Two-state mixed renewal processes for chronic disease.
Topics: Anti-Infective Agents; Bronchitis; Chronic Disease; Ciprofloxacin; Humans; Likelihood Functions; Mod | 1999 |
Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis.
Topics: Adult; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Female; Fluoroquinolones; Follow-Up St | 2000 |
The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Area Under Curve; Bronchiectasis; Bronchitis; | 2000 |
Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year.
Topics: Adult; Anti-Infective Agents; Bronchitis; Canada; Chronic Disease; Ciprofloxacin; Cost-Benefit Analy | 1999 |
Ciprofloxacin in the treatment of chronic bacterial prostatitis: a prospective, non-comparative multicentre clinical trial with long-term follow-up. The German Prostatitis Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Chronic Dis | 2000 |
Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Animals; Anti-Infective Agents; Chronic Di | 2000 |
Controlled multicenter study on chronic suppurative otitis media treated with topical applications of ciprofloxacin 0.2% solution in single-dose containers or combination of polymyxin B, neomycin, and hydrocortisone suspension.
Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Infective Agents; Chronic Disease; Ciprofloxa | 2000 |
Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome.
Topics: Adrenergic alpha-Antagonists; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Drug Therapy, C | 2002 |
Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome.
Topics: Adrenergic alpha-Antagonists; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Drug Therapy, C | 2002 |
Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome.
Topics: Adrenergic alpha-Antagonists; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Drug Therapy, C | 2002 |
Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome.
Topics: Adrenergic alpha-Antagonists; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Drug Therapy, C | 2002 |
Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome.
Topics: Adrenergic alpha-Antagonists; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Drug Therapy, C | 2002 |
Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome.
Topics: Adrenergic alpha-Antagonists; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Drug Therapy, C | 2002 |
Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome.
Topics: Adrenergic alpha-Antagonists; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Drug Therapy, C | 2002 |
Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome.
Topics: Adrenergic alpha-Antagonists; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Drug Therapy, C | 2002 |
Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome.
Topics: Adrenergic alpha-Antagonists; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Drug Therapy, C | 2002 |
Randomized, double-blind study of prulifloxacin versus ciprofloxacin in patients with acute exacerbations of chronic bronchitis.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Bronchitis; Chronic Disease; Ciprofloxacin; Dioxolan | 2002 |
Topical ciprofloxacin vs intramuscular gentamicin for chronic otitis media.
Topics: Administration, Topical; Adult; Chronic Disease; Ciprofloxacin; Female; Gentamicins; Humans; Injecti | 1992 |
Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment.
Topics: Child; Child, Preschool; Chronic Disease; Ciprofloxacin; Colistin; Cystic Fibrosis; Drug Therapy, Co | 1991 |
[Clinical studies on ciprofloxacin in chronic respiratory tract infection].
Topics: Administration, Oral; Adult; Aged; Chronic Disease; Ciprofloxacin; Female; Humans; Male; Middle Aged | 1991 |
[Clinical evaluation of ciprofloxacin in pulmonary infections in the patients with chronic respiratory diseases].
Topics: Adult; Aged; Chronic Disease; Ciprofloxacin; Female; Humans; Male; Middle Aged; Pneumonia; Respirato | 1991 |
Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Chronic Disease; Ciprofloxacin; Fema | 1990 |
Topical and oral treatment of chronic otitis media with ciprofloxacin. A preliminary study.
Topics: Administration, Oral; Administration, Topical; Adult; Chronic Disease; Ciprofloxacin; Drug Administr | 1990 |
Ciprofloxacin for the treatment of chronic ear disease.
Topics: Adult; Aged; Cholesteatoma; Chronic Disease; Ciprofloxacin; Clinical Trials as Topic; Female; Humans | 1989 |
Controlled prospective study of oral amoxycillin/clavulanate vs ciprofloxacin in acute exacerbations of chronic bronchitis.
Topics: Aged; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Bronchitis; Chronic Disease; Cipro | 1989 |
Therapy of acute and chronic gram-negative osteomyelitis with ciprofloxacin. Report from a Swedish Study Group.
Topics: Acute Disease; Administration, Oral; Arthritis; Bacterial Infections; Chronic Disease; Ciprofloxacin | 1988 |
The use of fluoroquinolones in chronic otitis suppurativa.
Topics: Cholesteatoma; Chronic Disease; Ciprofloxacin; Clinical Trials as Topic; Enoxacin; Humans; Mastoidit | 1987 |
Treatment of chronic postsurgical osteomyelitis with ciprofloxacin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Chronic Disease; Ciprofloxacin; Cl | 1987 |
Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis.
Topics: Adult; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Clinical Trials as Topic; Cystic Fibro | 1987 |
130 other studies available for ciprofloxacin and Chronic Illness
| Article | Year |
|---|---|
In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
Topics: Aerosols; Anti-Bacterial Agents; Bacteria; Biofilms; Chronic Disease; Ciprofloxacin; Colony Count, M | 2010 |
Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
Topics: Acute Disease; Administration, Oral; Animals; Antitubercular Agents; Bacterial Proteins; Biological | 2014 |
Analysis of pathogens and antimicrobial treatment in different groups of patients with chronic otitis media.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Chronic Disease; Ciprofloxacin; Escherichia coli; Fe | 2022 |
Effect of absorbable nasal packing saturated with ciprofloxacin and dexamethasone following endoscopic sinus surgery: A prospective cohort study.
Topics: Chronic Disease; Ciprofloxacin; Dexamethasone; Endoscopy; Epistaxis; Humans; Paranasal Sinuses; Pros | 2023 |
Effect of absorbable nasal packing saturated with ciprofloxacin and dexamethasone following endoscopic sinus surgery: A prospective cohort study.
Topics: Chronic Disease; Ciprofloxacin; Dexamethasone; Endoscopy; Epistaxis; Humans; Paranasal Sinuses; Pros | 2023 |
Effect of absorbable nasal packing saturated with ciprofloxacin and dexamethasone following endoscopic sinus surgery: A prospective cohort study.
Topics: Chronic Disease; Ciprofloxacin; Dexamethasone; Endoscopy; Epistaxis; Humans; Paranasal Sinuses; Pros | 2023 |
Effect of absorbable nasal packing saturated with ciprofloxacin and dexamethasone following endoscopic sinus surgery: A prospective cohort study.
Topics: Chronic Disease; Ciprofloxacin; Dexamethasone; Endoscopy; Epistaxis; Humans; Paranasal Sinuses; Pros | 2023 |
Effect of absorbable nasal packing saturated with ciprofloxacin and dexamethasone following endoscopic sinus surgery: A prospective cohort study.
Topics: Chronic Disease; Ciprofloxacin; Dexamethasone; Endoscopy; Epistaxis; Humans; Paranasal Sinuses; Pros | 2023 |
Effect of absorbable nasal packing saturated with ciprofloxacin and dexamethasone following endoscopic sinus surgery: A prospective cohort study.
Topics: Chronic Disease; Ciprofloxacin; Dexamethasone; Endoscopy; Epistaxis; Humans; Paranasal Sinuses; Pros | 2023 |
Effect of absorbable nasal packing saturated with ciprofloxacin and dexamethasone following endoscopic sinus surgery: A prospective cohort study.
Topics: Chronic Disease; Ciprofloxacin; Dexamethasone; Endoscopy; Epistaxis; Humans; Paranasal Sinuses; Pros | 2023 |
Effect of absorbable nasal packing saturated with ciprofloxacin and dexamethasone following endoscopic sinus surgery: A prospective cohort study.
Topics: Chronic Disease; Ciprofloxacin; Dexamethasone; Endoscopy; Epistaxis; Humans; Paranasal Sinuses; Pros | 2023 |
Effect of absorbable nasal packing saturated with ciprofloxacin and dexamethasone following endoscopic sinus surgery: A prospective cohort study.
Topics: Chronic Disease; Ciprofloxacin; Dexamethasone; Endoscopy; Epistaxis; Humans; Paranasal Sinuses; Pros | 2023 |
Controlled delivery of ciprofloxacin and ivacaftor via sinus stent in a preclinical model of Pseudomonas sinusitis.
Topics: Aminophenols; Animals; Chronic Disease; Ciprofloxacin; Maxillary Sinus; Pseudomonas; Pseudomonas Inf | 2020 |
Chronic Suppurative Otitis Media: A Case Report.
Topics: Adult; Anti-Bacterial Agents; Chronic Disease; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; | 2020 |
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment.
Topics: Acute Disease; Advisory Committees; Algorithms; Anti-Bacterial Agents; Biological Products; Budesoni | 2020 |
Rhinoscleroma: a chronic infectious disease of poor areas with characteristic histological features - report of a series of six cases.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Chronic Disease; Ciprofloxacin; Female; Humans; Mal | 2018 |
Recurrent otorrhea in chronic suppurative otitis media: is biofilm the missing link?
Topics: Administration, Topical; Adolescent; Adult; Anti-Bacterial Agents; Biofilms; Child; Child, Preschool | 2017 |
Live birth rate following oral antibiotic treatment for chronic endometritis in infertile women with repeated implantation failure.
Topics: Administration, Oral; Adult; Birth Rate; Chronic Disease; Ciprofloxacin; Endometritis; Female; Human | 2017 |
Sweetening Inhaled Antibiotic Treatment for Eradication of Chronic Respiratory Biofilm Infection.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Biofilms; Cell Line, Tumor; Chronic Disease; Cipr | 2018 |
Antinociceptive antibiotics-loaded into solid lipid nanoparticles of prolonged release: Measuring pharmacological efficiency and time span on chronic monoarthritis rats.
Topics: Analgesics; Animals; Anti-Bacterial Agents; Arthritis; Chronic Disease; Ciprofloxacin; Delayed-Actio | 2018 |
Synergistic effect of immunomodulatory S100A8/A9 and ciprofloxacin against Pseudomonas aeruginosa biofilm in a murine chronic wound model.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Calgranulin A; Chronic Disease; Ciprofloxacin; Colony Coun | 2020 |
Bacterial profile and antimicrobial susceptibility patterns in chronic suppurative otitis media at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Chronic Disease; Ciprofloxacin; Clarithromyci | 2019 |
Chitosan-polycaprolactone blend sponges for management of chronic osteomyelitis: A preliminary characterization and in vitro evaluation.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Biocompatible Materials; Ce | 2019 |
Two cases of Kerstersia gyiorum isolated from sites of chronic infection.
Topics: Alcaligenaceae; Anti-Bacterial Agents; Bacteriological Techniques; Chronic Disease; Ciprofloxacin; D | 2013 |
Human mesenchymal stromal cells can uptake and release ciprofloxacin, acquiring in vitro anti-bacterial activity.
Topics: Anti-Bacterial Agents; Blood Bactericidal Activity; Bone and Bones; Cell- and Tissue-Based Therapy; | 2014 |
Induction of prophages by fluoroquinolones in Streptococcus pneumoniae: implications for emergence of resistance in genetically-related clones.
Topics: Blotting, Southern; Chronic Disease; Ciprofloxacin; Disease Progression; Drug Resistance, Bacterial; | 2014 |
In vitro efficacy of N-acetylcysteine on bacteria associated with chronic suppurative otitis media.
Topics: Acetylcysteine; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Chronic Di | 2014 |
Chronic bacterial seminal vesiculitis as a potential disease entity in men with chronic prostatitis.
Topics: Adult; Bacterial Infections; Chronic Disease; Ciprofloxacin; Humans; Male; Middle Aged; Organotechne | 2015 |
Difference of Type 3 secretion system (T3SS) effector gene genotypes (exoU and exoS) and its implication to antibiotics resistances in isolates of Pseudomonas aeruginosa from chronic otitis media.
Topics: ADP Ribose Transferases; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; | 2017 |
Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Child; C | 2008 |
Clinicobacteriological study of chronic dacryocystitis in adults.
Topics: Adult; Age Factors; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Chloramphenicol; Chronic Dis | 2008 |
The costs of treatment of early and chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.
Topics: Adult; Anti-Bacterial Agents; Ceftazidime; Child, Preschool; Chronic Disease; Ciprofloxacin; Clavula | 2009 |
Chronic bone infections due to Enterobacter cloacae: current therapeutic trends and clinical outcome.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bone Diseases, Infectious; Carbapenems; Chronic Dise | 2009 |
The effect of topical ciprofloxacin and steroid-containing ear drops for chronic suppurative otitis media on the internal ear.
Topics: Administration, Topical; Animals; Anti-Infective Agents; Audiometry; Chronic Disease; Ciprofloxacin; | 2010 |
[Chronic prostatitis and biofilm].
Topics: Adult; Biofilms; Chronic Disease; Ciprofloxacin; Contraception Behavior; Diet; Disease Susceptibilit | 2009 |
Fluoroquinolone-resistant Pseudomonas aeruginosa in chronic rhinosinusitis.
Topics: Anti-Bacterial Agents; Chronic Disease; Ciprofloxacin; Comorbidity; Drug Resistance, Bacterial; Fluo | 2009 |
Chronic suppurative otitis media in cleft palate: microorganism etiology and susceptibilities.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacteria; Child; Child, Preschool; Chronic Disease; Ciprof | 2009 |
Ecthyma-gangrenosum-like bullous pemphigoid.
Topics: Adrenal Cortex Hormones; Aged, 80 and over; Anti-Bacterial Agents; Autoantibodies; Autoantigens; Chr | 2010 |
The effectiveness of endoscopic epidurolysis in treatment of degenerative chronic low back pain: a prospective analysis and follow-up at 48 months.
Topics: Aged; Chronic Disease; Ciprofloxacin; Cohort Studies; Endoscopy; Epidural Space; Female; Follow-Up S | 2011 |
Chemical ear peeling: a simple technique for the treatment of chronic external otitis: how we do it.
Topics: Acetic Acid; Bacterial Infections; Chemexfoliation; Chronic Disease; Ciprofloxacin; Cortisone; Drug | 2010 |
Malignancy or inflammation? A case report of a young man with fever of unknown origin.
Topics: Adult; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Fever of Unknown Origin; Humans; Male; | 2011 |
Fluoroquinolone-macrolide combination therapy for chronic bacterial prostatitis: retrospective analysis of pathogen eradication rates, inflammatory findings and sexual dysfunction.
Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Infections; Chronic Disease; Ciprofloxacin; Cohort St | 2011 |
Preventive effect of selenium on chronic bacterial prostatitis.
Topics: Animals; Body Weight; Chronic Disease; Ciprofloxacin; Colony Count, Microbial; Escherichia coli; Esc | 2012 |
Chronic spinal cord abscess in an elderly patient.
Topics: Abscess; Adrenal Cortex Hormones; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents | 2011 |
The value of successive Infecton scans in assessing the presence of chronic bone and joint infection and in predicting its evolution after treatment and after a prolonged follow-up.
Topics: Adult; Aged; Arthrography; Blood Sedimentation; Bone and Bones; Bone Diseases, Infectious; C-Reactiv | 2011 |
Clinical features and management of pouchitis in Japanese ulcerative colitis patients.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Age of Onset; Aged; Anti-Bacterial Agents; Asian Peop | 2013 |
Pattern of bacterial isolates in the middle ear discharge of patients with chronic suppurative otitis media in a tertiary hospital in North central Nigeria.
Topics: Adolescent; Adult; Age Distribution; Anti-Bacterial Agents; Child; Child, Preschool; Chronic Disease | 2012 |
Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection.
Topics: Acute Disease; Animals; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Disease Progression; | 2002 |
Cost effectiveness model comparing trimethoprim sulfamethoxazole and ciprofloxacin for the treatment of chronic bacterial prostatitis.
Topics: Anti-Infective Agents; Bacterial Infections; Chronic Disease; Ciprofloxacin; Cost-Benefit Analysis; | 2002 |
Delayed and prolonged cholestatic hepatitis with ductopenia after long-term ciprofloxacin therapy for Crohn's disease.
Topics: Anti-Infective Agents; Bile Ducts; Chemical and Drug Induced Liver Injury; Cholestasis; Chronic Dise | 2002 |
[The clinical investigation of bacteriology of chronic suppurative otitis media].
Topics: Adolescent; Adult; Bacteria, Anaerobic; Child; Chronic Disease; Ciprofloxacin; Female; Humans; Male; | 2001 |
[Ciprofloxacin in the treatment of patients with brucellosis].
Topics: Acute Disease; Adult; Antibody Formation; Brucella melitensis; Brucellosis; Chronic Disease; Ciprofl | 2002 |
[Infectious distribution and resistant of Neisseria gonorrhoeae, Mycoplasma, and Chlamydia trachomatis in the chronic prostatitis].
Topics: Adult; Chlamydia Infections; Chlamydia trachomatis; Chronic Disease; Ciprofloxacin; Erythromycin; Go | 2003 |
[Ciprofloxacin treatment of patients with acute and chronic otitis].
Topics: Acute Disease; Adult; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Female; Humans; Male; M | 2003 |
Management of chronic suppurative otitis media.
Topics: Administration, Topical; Anti-Infective Agents; Child; Child, Preschool; Chronic Disease; Ciprofloxa | 2004 |
Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center.
Topics: Adolescent; Anti-Infective Agents; Child; Child, Preschool; Chronic Disease; Ciprofloxacin; Cystic F | 2004 |
Management of chronic suppurative otitis media.
Topics: Administration, Topical; Anti-Infective Agents; Australia; Child; Child, Preschool; Chronic Disease; | 2004 |
Ciprofloxacin in the treatment of chronic suppurative otitis media.
Topics: Acetates; Administration, Topical; Adult; Aged; Anti-Infective Agents; Child; Chronic Disease; Cipro | 2004 |
Emergence of ciprofloxacin-resistant pseudomonas in chronic suppurative otitis media.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Drug Resistance, Bac | 2004 |
Bronchus-associated lymphoid tissue lymphoma arising in a patient with bronchiectasis and chronic Mycobacterium avium infection.
Topics: Aged; Anti-Infective Agents; Bronchial Neoplasms; Bronchiectasis; Chronic Disease; Ciprofloxacin; Cl | 2004 |
[Ulcerative colitis. Chronic active course].
Topics: Administration, Oral; Adult; Age Factors; Anti-Infective Agents; Azathioprine; Child; Chronic Diseas | 2004 |
Treatment of experimental osteomyelitis by liposomal antibiotics.
Topics: Animals; Anti-Bacterial Agents; Chronic Disease; Ciprofloxacin; Drug Carriers; Drug Therapy, Combina | 2004 |
Summaries for patients. Treating men with chronic prostatitis/chronic pelvic pain syndrome.
Topics: Adrenergic alpha-Antagonists; Adult; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Double-B | 2004 |
Treating chronic prostatitis: antibiotics no, alpha-blockers maybe.
Topics: Adrenergic alpha-Antagonists; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Humans; Male; P | 2004 |
Serum and gingival crevicular fluid levels of ciprofloxacin in patients with periodontitis.
Topics: Adult; Anti-Infective Agents; Chromatography, High Pressure Liquid; Chronic Disease; Ciprofloxacin; | 2004 |
[A case of pulmonary multiresistant Mycobacterium bovis tuberculosis in Madagascar].
Topics: Amikacin; Antitubercular Agents; Capreomycin; Chronic Disease; Ciprofloxacin; Cough; DNA, Bacterial; | 2003 |
Oxymetazoline is equivalent to ciprofloxacin in preventing postoperative otorrhea or tympanostomy tube obstruction.
Topics: Administration, Topical; Adolescent; Adrenergic alpha-Agonists; Anti-Infective Agents; Antibiotic Pr | 2005 |
[Clinical-laboratory study of the efficacy of combined drug Cifran CT in complex therapy of inflammatory periodontal disease].
Topics: Adult; Bacteria; Bacterial Infections; Chronic Disease; Ciprofloxacin; Female; Fluoroquinolones; Hum | 2005 |
Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis.
Topics: Adult; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Drug Therapy, Combination; Female; Hum | 2005 |
Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cephalosporins; Child; Child, Preschool; Chronic Disease; | 2005 |
Synergistic effect between catechin and ciprofloxacin on chronic bacterial prostatitis rat model.
Topics: Animals; Anti-Infective Agents; Catechin; Chronic Disease; Ciprofloxacin; Colony Count, Microbial; D | 2005 |
[Ciprofloxacin-induced acute non-oliguric renal failure in patient with chronic glomerulonephritis].
Topics: Acute Kidney Injury; Adult; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Female; Glomerulo | 2005 |
The gingival crevicular fluid ciprofloxacin level in subjects with gingivitis and periodontitis, and its effects on clinical parameters.
Topics: Actinobacillus Infections; Adult; Aggregatibacter actinomycetemcomitans; Anti-Infective Agents; Chro | 2005 |
Efficacy and safety of ciprofloxacin in gynaecological infections.
Topics: Acute Disease; Administration, Oral; Anti-Infective Agents; Bacterial Infections; Chronic Disease; C | 1989 |
Effects of chronic bacterial prostatitis on prostate specific antigen levels total and free in patients with benign prostatic hyperplasia and prostate cancer.
Topics: Adult; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Ciprofloxaci | 2006 |
Re: treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Ciprofloxacin; | 2006 |
Interleukin-1, interleukin-6, and interleukin-10 responses after antibiotic treatment in experimental chronic Staphylococcus aureus osteomyelitis.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Cefuroxime; Chronic Disease; Ciprofloxacin; Disease Models | 2006 |
[Taxonomic spectrum and antibiotic resistance of Enterobacteriaceae isolated from bile of patients with cholangitis].
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Amoxicillin; Anti-Bacterial Agents; Bile; Cefazolin; Cefot | 2006 |
Chronic diarrhea due to a single strain of Aeromonas caviae.
Topics: Aeromonas; Chronic Disease; Ciprofloxacin; Diarrhea; DNA, Bacterial; Feces; Gram-Negative Bacterial | 1995 |
Pharmacokinetic study of fibrin clot-ciprofloxacin complex: an in vitro and in vivo experimental investigation.
Topics: Animals; Anti-Infective Agents; Biodegradation, Environmental; Chronic Disease; Ciprofloxacin; Drug | 1995 |
Ciprofloxacin advertising in CMAJ.
Topics: Acute Disease; Advertising; Bronchitis; Chronic Disease; Ciprofloxacin; Drug Resistance, Microbial; | 1993 |
Oral ciprofloxacin for treatment of chronic osteomyelitis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ampicillin; Bacterial Infections; Chronic Dise | 1993 |
Ciprofloxacin-resistant Haemophilus influenzae infection in a patient with chronic lung disease.
Topics: Adult; Chronic Disease; Ciprofloxacin; Drug Resistance, Microbial; Haemophilus Infections; Haemophil | 1993 |
[Treatment of chronic brucellosis with ciprofloxacin. Personal experience].
Topics: Adult; Brucellosis; Chronic Disease; Ciprofloxacin; Female; Humans; Male; Middle Aged | 1993 |
Treatment of chronic postfiltration hypotony by intrableb injection of autologous blood.
Topics: Aged; Aged, 80 and over; Blood; Chronic Disease; Ciprofloxacin; Female; Humans; Injections; Intraocu | 1993 |
In vitro susceptibility to ciprofloxacin of bacterial strains isolated from chronic otitis media and chronic sinusitis.
Topics: Adult; Anti-Infective Agents; Bacteria; Chronic Disease; Ciprofloxacin; Drug Resistance, Microbial; | 1995 |
Quinolone resistance in Oligella urethralis-associated chronic ambulatory peritoneal dialysis peritonitis.
Topics: Adult; Aged; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Drug Resistance, Microbial; Huma | 1996 |
Susceptibility of microorganisms isolated from chronic suppurative otitis media to ciprofloxacin.
Topics: Anti-Infective Agents; Bacteria; Chronic Disease; Ciprofloxacin; Drug Resistance, Microbial; Humans; | 1996 |
Effect of 6-fluoro-8-methoxy quinolone (AM-1155) against chronic airway infection with Pseudomonas aeruginosa in a rat model.
Topics: Animals; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Disease Models, Animal; Fluoroquinol | 1997 |
[Ciprofloxacin in the treatment of urogenital infections in women].
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Chlamydia Infections; Chronic Disease; Ciprofloxacin | 1997 |
[Treatment of lower respiratory tract infections in the elderly].
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; A | 1997 |
A new dosage regimen for topical application of ciprofloxacin in the management of chronic suppurative otitis media.
Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Infective Agents; Chronic Disease; Ciprofloxa | 1998 |
[The role of ciprofloxacin in the management of chronic sinusitis].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Humans; Sinusitis | 1998 |
[The role of ciprofloxacin in the treatment of chronic bronchitis].
Topics: Acute Disease; Anti-Infective Agents; Bacterial Infections; Bronchitis; Chronic Disease; Ciprofloxac | 1998 |
[Bacteriology in community-acquired respiratory pathology].
Topics: Acute Disease; Ambulatory Care; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Ciprof | 1998 |
Treatment of chronic suppurative otitis media with topical ciprofloxacin.
Topics: Administration, Topical; Animals; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Disease Mod | 1998 |
[Role of ciprofloxacin in the treatment of chronic otitis media].
Topics: Administration, Oral; Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; A | 1998 |
Synoviocyte-packaged Chlamydia trachomatis induces a chronic aseptic arthritis.
Topics: Animals; Arthritis, Reactive; Bacterial Outer Membrane Proteins; Blotting, Western; Chlamydia Infect | 1998 |
Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis.
Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Bronchitis; Chronic Disease; Ciprofloxacin; Cost- | 1999 |
Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis.
Topics: Adult; Chronic Disease; Ciprofloxacin; Drug Resistance, Microbial; Drug Therapy, Combination; Female | 1999 |
Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis.
Topics: Adult; Chronic Disease; Ciprofloxacin; Drug Resistance, Microbial; Drug Therapy, Combination; Female | 1999 |
Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis.
Topics: Adult; Chronic Disease; Ciprofloxacin; Drug Resistance, Microbial; Drug Therapy, Combination; Female | 1999 |
Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis.
Topics: Adult; Chronic Disease; Ciprofloxacin; Drug Resistance, Microbial; Drug Therapy, Combination; Female | 1999 |
National guideline for the management of prostatitis. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases).
Topics: Adrenergic alpha-Antagonists; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, U | 1999 |
The role of the resident intestinal flora in acute and chronic dextran sulfate sodium-induced colitis in mice.
Topics: Acute Disease; Animals; Anti-Bacterial Agents; Biopsy; Body Weight; Chronic Disease; Ciprofloxacin; | 2000 |
Primary and combined resistance to four antimicrobial agents in Helicobacter pylori in Sofia, Bulgaria.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bulgaria; Child; Child, Preschool; Chronic Disease; | 2000 |
[Bacteriologic evaluation of otitis externa and chronic otitis media].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Aspergillus; Bacteria; Candida; Child; Chronic | 2000 |
Usefulness of 99mTc-ciprofloxacin (infecton) scan in diagnosis of chronic orthopedic infections: comparative study with 99mTc-HMPAO leukocyte scintigraphy.
Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Bone and Bones; Child; Child, Preschool; Chron | 2001 |
A simple infection model using pre-colonized implants to reproduce rat chronic Staphylococcus aureus osteomyelitis and study antibiotic treatment.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Biofilms; Cefuroxime; Cephalosporins; Chronic | 2001 |
[Chronic ORL infections of the adult in the community. Role of ciprofloxacin].
Topics: Anti-Infective Agents; Bacterial Infections; Chronic Disease; Ciprofloxacin; Humans; Otitis Media; S | 2001 |
Chronic vulvovaginitis caused by antibiotic-resistant Shigella flexneri in a prepubertal child.
Topics: Anti-Infective Agents; Child; Chronic Disease; Ciprofloxacin; Drug Resistance; Dysentery, Bacillary; | 2002 |
[Current therapeutical management, new antibiotics and treatment of Pseudomonas aeruginosa in bacterial ENT-infections].
Topics: Ceftazidime; Chronic Disease; Ciprofloxacin; Clinical Trials as Topic; Dose-Response Relationship, D | 2002 |
Imaging prostatitis with Tc-99m ciprofloxacin.
Topics: Acute Disease; Bacterial Infections; Chronic Disease; Ciprofloxacin; Humans; Male; Organotechnetium | 2002 |
Comparative clinical and microbiological study of amoxycillin-clavulanic acid and ciprofloxacin in acute purulent exacerbations of chronic bronchitis.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Bacteria | 1992 |
Oral ciprofloxacin in the management of chronic suppurative otitis media without cholesteatoma in children: preliminary experience in 21 children.
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Cholesteatoma; Chronic Disease; Ciproflox | 1992 |
Surgical management of chronic tophaceous gout. A case report.
Topics: Aged; Chronic Disease; Ciprofloxacin; Foot Deformities, Acquired; Gout; Humans; Male; Metatarsophala | 1992 |
[Pharmacokinetics and clinical efficacy of ciprofloxacin in aged patients with chronic respiratory diseases].
Topics: Aged; Aged, 80 and over; Chronic Disease; Ciprofloxacin; Drug Evaluation; Humans; Respiratory Tract | 1992 |
Antibiotic-induced release of endotoxin in chronically bacteriuric patients.
Topics: Anti-Bacterial Agents; Bacteriuria; Chronic Disease; Ciprofloxacin; Colony Count, Microbial; Endotox | 1991 |
Refractory chronic bacterial prostatitis: a re-evaluation of ciprofloxacin treatment after a median followup of 30 months.
Topics: Administration, Oral; Adult; Chronic Disease; Ciprofloxacin; Drug Evaluation; Escherichia coli Infec | 1991 |
Ciprofloxacin: drug of choice in the treatment of malignant external otitis (MEO).
Topics: Aged; Aged, 80 and over; Chronic Disease; Ciprofloxacin; Female; Follow-Up Studies; Humans; Male; Mi | 1991 |
Nontyphoidal Salmonella pleuropulmonary infections.
Topics: Aged; Chronic Disease; Ciprofloxacin; Empyema; Humans; Male; Salmonella Infections | 1991 |
MICs of ciprofloxacin and trimethoprim for Escherichia coli: influence of pH, inoculum size and various body fluids.
Topics: Animals; Body Fluids; Chronic Disease; Ciprofloxacin; Dogs; Dose-Response Relationship, Drug; Escher | 1991 |
Oral ciprofloxacin compared with standard parenteral antibiotic therapy for chronic osteomyelitis in adults.
Topics: Administration, Oral; Adult; Aged; Chronic Disease; Ciprofloxacin; Clindamycin; Drug Therapy, Combin | 1990 |
Relapsing yersinia infection.
Topics: Adult; Chronic Disease; Ciprofloxacin; Female; Humans; Recurrence; Yersinia enterocolitica; Yersinia | 1990 |
Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis.
Topics: Animals; Chronic Disease; Ciprofloxacin; Disease Models, Animal; Drug Therapy, Combination; Male; Me | 1990 |
Effect of renal function on the bioavailability of ciprofloxacin.
Topics: Administration, Oral; Adult; Biological Availability; Chronic Disease; Ciprofloxacin; Female; Glomer | 1990 |
Treatment of chronic osteomyelitis with ciprofloxacin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacteria; Chronic Disease; Ciprofloxacin; Exudates and T | 1989 |
Treatment of chronic Salmonella carriers with ciprofloxacin.
Topics: Adult; Aged; Carrier State; Chronic Disease; Ciprofloxacin; Female; Follow-Up Studies; Humans; Infan | 1987 |
[New oral quinolone compounds in chronic bronchitis].
Topics: Administration, Oral; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Chronic Disease; Cipr | 1986 |
Ciprofloxacin in oral treatment of ear infections.
Topics: Administration, Oral; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Female; Humans; Male; O | 1986 |
Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis.
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Chronic Disease; Ciprofloxacin; Drug | 1986 |
Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.
Topics: Abscess; Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Bronchopneumonia; Chi | 1986 |
[Ciprofloxacin and cefotaxim: pharmacokinetic and therapeutic effectiveness in E. coli pyelonephritis in rats].
Topics: Acute Disease; Animals; Anti-Infective Agents, Urinary; Cefotaxime; Chronic Disease; Ciprofloxacin; | 1986 |
Osteomyelitis of the maxilla with associated vertical root fracture and Pseudomonas infection.
Topics: Adult; Chronic Disease; Ciprofloxacin; Humans; Incisor; Male; Maxillary Diseases; Osteomyelitis; Pse | 1988 |
Ciprofloxacin as therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Bone and Bones; Chronic Disease; Ciprofloxacin; Drug Resistance, Mic | 1985 |
Treatment of chronic osteomyelitis with ciprofloxacin.
Topics: Adult; Aged; Bacterial Infections; Chronic Disease; Ciprofloxacin; Female; Humans; Male; Middle Aged | 1987 |
Ciprofloxacin therapy in complicated urinary tract infections caused by Pseudomonas aeruginosa and other resistant bacteria.
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Ciprofloxacin; Escherichia coli Infections; Female; | 1986 |
Ciprofloxacin: multiple-dose pharmacokinetic and clinical results in patients with hypercrinic bronchopulmonary diseases.
Topics: Adult; Aged; Bronchitis; Chronic Disease; Ciprofloxacin; Humans; Kinetics; Lung; Male; Middle Aged; | 1987 |
Oral ciprofloxacin in refractory gram-negative bacillary infections.
Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Chronic Disease; Ciprofloxacin; Female; Gram-N | 1987 |
Ciprofloxacin in the treatment of urinary and respiratory tract infections in patients with chronic liver disease.
Topics: Adult; Aged; Chronic Disease; Ciprofloxacin; Female; Humans; Liver Diseases; Male; Middle Aged; Resp | 1986 |
The efficacy and safety of ciprofloxacin in the treatment of chronic Pseudomonas aeruginosa urinary tract infection.
Topics: Adult; Aged; Chronic Disease; Ciprofloxacin; Female; Humans; Male; Middle Aged; Pseudomonas Infectio | 1986 |